UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to_____

Commission File Number 001-36533

MEDAVAIL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

90-0772394

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

~~6665 Millcreek Dr. Unit 1, Mississauga ON Canada~~4720 East Cotton Gin Loop, Suite 220, Phoenix, Arizona

~~L5N 5M4~~85040

(Address of principal executive offices)

(Zip Code)

+1 (905) 812-0023

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

MDVL

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May ~~11, 2022,~~5, 2023, there were ~~70,555,977~~80,523,932 shares of the registrant’s common stock outstanding.

MedAvail Holdings, Inc.

Form 10-Q

For the Three Months Ended March 31, ~~2022~~2023

TABLE OF CONTENTS


		Page

PART I
Item 1.	Financial Statements (Unaudited)	5
	Condensed Consolidated ~~Condensed~~ Balance Sheets	5
	Condensed Consolidated ~~Condensed~~ Statements of Operations and Comprehensive Loss	57
	Condensed Consolidated ~~Condensed~~ Statements of ~~Shareholders'~~Stockholders' Equity ~~(Deficit)~~	68
	Condensed Consolidated ~~Condensed~~ Statements of Cash Flows	79
	Notes to Condensed Consolidated ~~Condensed~~ Financial Statements	911
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	2023
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	2730
Item 4.	Controls and Procedures	2730

PART II
Item 1.	Legal Proceedings	2831
Item 1A.	Risk Factors	2831
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2832
Item 3.	Defaults Upon Senior Securities	2832
Item 4.	Mine Safety Disclosures	2832
Item 5.	Other Information	2832
Item 6.	Exhibits	2933

Signatures		3034

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein ~~that are~~ not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

These forward-looking statements include, but are not limited to, statements about:

•the impact of our decision to exit our pharmacy services business and related asset sales and reductions in force;

•our plans to modify our current products, or develop new products;

•the expected growth of our business and organization;

•our expectations regarding the size of our sales organization and expansion of our sales and marketing efforts;

•our ability to retain and recruit key personnel, including the continued development of a sales and marketing infrastructure;

•our ability to obtain and maintain intellectual property protection for our products;

•our ability to expand our business into new geographic markets;

•our compliance with extensive Nasdaq requirements and government laws, rules and regulations both in the United States and internationally;

•our estimates of expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing;

•our ability to identify and develop new and planned products and/or acquire new products;

•~~the expectations regarding the impact of the COVID-19 pandemic on our business;~~

•existing regulations and regulatory developments in the United States, Canada and other jurisdictions;

•the impact of laws and regulations;

•our financial performance;

•the period over which we estimate our existing cash, cash equivalents and available-for-sale investments will be sufficient to fund our future operating expenses and capital expenditure requirements;

•our anticipated use of our existing resources; ~~and~~

•developments and projections relating to our competitors or our ~~industry.~~industry; and

•the impact of general market and macroeconomic conditions, the effect of inflationary pressure, including any impact of adverse developments affecting the financial services industry, such as those based on liquidity constraints or concerns and events including the outbreak of war in Ukraine, on our business.

We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we ~~operate and~~operate. These forward-looking statements are management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this Quarterly Report on Form ~~10-Q.~~10-Q and in our Annual Report on Form 10-K filed

with the Securities and Exchange Commission, or SEC. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any

forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the SEC as exhibits to ~~the~~this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

PART I

Item 1. Financial Statements

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated ~~Condensed~~ Balance Sheets

(Unaudited)

(in ~~thousands, except share amounts)~~thousands)

March 31, December 31,
2022 2021
Assets
Current assets:
Cash and cash equivalents $ 5,274 $ 19,689
Restricted cash 676 400
Accounts receivable (net of allowance for doubtful accounts of $96 thousand for March 31, 2022, $66 thousand for December 31, 2021) 1,748 1,189
Inventories 5,088 3,916
Prepaid expenses and other current assets 3,105 2,191
Total current assets 15,891 27,385
Property, plant and equipment, net 6,175 5,692
Intangible assets, net 2,765 2,300
Right-of-use assets 2,628 2,538
Other assets 233 228
Total assets $ 27,692 $ 38,143
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities $ 8,527 $ 6,740
Deferred revenue 107 83
Current portion of lease obligations 733 682
Total current liabilities 9,367 7,505
Long-term debt, net 9,608 9,538
Long-term portion of lease obligations 2,102 2,027
Total liabilities 21,077 19,070
Commitments and contingencies 0 0
Stockholders' deficit:
Common shares ($0.001 par value, 100,000,000 shares authorized, 32,908,922 and 32,902,048 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively) 33 33
Warrants 1,373 1,373
Additional paid-in-capital 217,249 216,685
Accumulated other comprehensive loss (6,928) (6,928)
Accumulated deficit (205,112) (192,090)
Total stockholders' equity 6,615 19,073
Total liabilities and stockholders' equity $ 27,692 $ 38,143


	March 31, 2023		December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$	18,796	$	11,444
Restricted cash	676		676
Accounts receivable	207		404
Inventories	8,701		3,994
Prepaid expenses and other current assets	2,072		2,569

Current assets from discontinued operations	2,079		4,842
Total current assets	32,531		23,929
Property, plant and equipment, net	789		5,261
Intangible assets, net	425		451
Right-of-use assets	773		624
Other assets	30		30

Long-term assets from discontinued operations	1,166		2,837
Total assets	$	35,714	$	33,132

The accompanying notes are an integral part of these unaudited condensed consolidated ~~condensed~~ financial statements.

~~Going concern (Note 2).~~

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated Balance Sheets (Continued)

(Unaudited)

(in thousands, except share and per share amounts)


	March 31, 2023		December 31, 2022
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	898	$	818
Accrued liabilities	592		552
Accrued payroll and benefits	1,240		1,379
Deferred revenue	275		152
Current portion of lease obligations	244		246

Current liabilities from discontinued operations	1,885		2,794
Total current liabilities	5,134		5,941
Warrant liabilities	23,378		—
Long-term debt, net	1,428		4,798
Long-term portion of lease obligations	590		441
Long-term liabilities from discontinued operations	1,015		1,128
Total liabilities	31,545		12,308
Commitments and contingencies (Note 10)
Stockholders' equity:
Common shares ($0.001 par value, 300,000,000 shares authorized, 80,480,641 and 80,169,719 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively)	81		81
Warrants	11,205		11,148
Additional paid-in-capital	256,847		256,229
Accumulated other comprehensive loss	(6,928)		(6,928)
Accumulated deficit	(257,036)		(239,706)
Total stockholders' equity	4,169		20,824
Total liabilities and stockholders' equity	$	35,714	$	33,132

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated ~~Condensed~~ Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per-share amounts)


		Three Months Ended March 31,						Three Months Ended March 31,
			2022		2021				2023		2022
Revenue:	Revenue:						Revenue:
Pharmacy and hardware revenue			$	9,014	$	3,781
Hardware and subscription revenue							Hardware and subscription revenue		$	304	$	165
Service revenue	Service revenue		100		246		Service revenue		316		100
Total revenue	Total revenue		9,114		4,027		Total revenue		620		265
Cost of products sold and services:	Cost of products sold and services:						Cost of products sold and services:
Pharmacy and hardware cost of products sold			8,563		3,526
Hardware cost of products sold							Hardware cost of products sold		245		81
Service costs	Service costs		50		181		Service costs		118		50
Total cost of products sold and services	Total cost of products sold and services		8,613		3,707		Total cost of products sold and services		363		131
Operating expense:
Other operating expenses:							Other operating expenses:

Pharmacy operations			3,929		2,593
General and administrative	General and administrative		6,535		5,676		General and administrative		4,960		5,190
Selling and marketing	Selling and marketing		2,313		1,534		Selling and marketing		132		100
Research and development	Research and development		493		168		Research and development		176		258

Total operating expense	Total operating expense		13,270		9,971		Total operating expense		5,268		5,548
Operating loss	Operating loss		(12,769)		(9,651)		Operating loss		(5,011)		(5,414)
Other gain (loss), net			—		161

Loss on issuance of warrants							Loss on issuance of warrants		(10,424)		—
Gain from change in fair value of warrant liabilities							Gain from change in fair value of warrant liabilities		3,045		—
Interest income	Interest income		1		40		Interest income		1		1
Interest expense	Interest expense		(254)		(2)		Interest expense		(169)		(251)
Loss before income taxes			(13,022)		(9,452)
Income tax expense			—		—
Net loss and comprehensive loss			$	(13,022)	$	(9,452)
Net loss per share - basic and diluted			$	(0.40)	$	(0.27)

Net loss and comprehensive loss from continued operations							Net loss and comprehensive loss from continued operations		(12,558)		(5,664)
Discontinued operations:							Discontinued operations:
Loss from discontinued operations							Loss from discontinued operations		(4,772)		(7,358)

Net loss							Net loss		$	(17,330)	$	(13,022)

Basic and diluted net loss per share:							Basic and diluted net loss per share:
Loss from continued operations							Loss from continued operations		$	(0.16)	$	(0.17)
Loss from discontinued operations							Loss from discontinued operations		$	(0.06)	$	(0.22)
Weighted average shares outstanding - basic and diluted	Weighted average shares outstanding - basic and diluted		32,921,969		34,439,953		Weighted average shares outstanding - basic and diluted		80,270,494		32,921,969

The accompanying notes are an integral part of these unaudited condensed consolidated ~~condensed~~ financial statements.

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated ~~Condensed~~ Statements of ~~Shareholders'~~Stockholders' Equity

(Unaudited)

(in thousands, except ~~per~~ share amounts)


		Common Shares			Warrants			Additional Paid-in-Capital			Accumulated Deficit				Accumulated Other Comprehensive Loss				Total Stockholders' Equity			Common Shares										Warrants		Additional Paid-in-Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss				Total Stockholders' Equity
		Shares	Amount											Shares						Amount						Warrants		Additional Paid-in-Capital	Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity

Balance at December 31, 2021		32,902,048	$	33		$	1,373					$	216,685					$	(192,090)			$	(6,928)		$					19,073
Balance at December 31, 2022																							Balance at December 31, 2022	80,169,719			$	81						$	11,148	$	256,229			$	(239,706)			$	(6,928)	$	20,824
Net loss	Net loss	—	—			—			—			(13,022)				—				(13,022)			Net loss	—			—							—		—		(17,330)				—		(17,330)
Shares issued for vested RSUs	Shares issued for vested RSUs	6,874	—			—			—			—				—				—			Shares issued for vested RSUs	310,922			—							—		—		—				—		—

Warrants issued																							Warrants issued	—			—							57		—		—				—		57
Share-based compensation	Share-based compensation	—	—			—			564			—				—				564			Share-based compensation	—			—							—		618		—				—		618
Balance at March 31, 2022		32,908,922	$	33		$	1,373		$	217,249		$	(205,112)			$	(6,928)			$	6,615
Balance at March 31, 2023																							Balance at March 31, 2023	80,480,641			$	81						$	11,205	$	256,847	$	(257,036)			$	(6,928)	$	4,169

Balance at December 31, 2020		31,816,020	32			2,614			213,624			(148,275)				(6,928)				61,067
Balance at December 31, 2021																							Balance at December 31, 2021	32,902,048			$	33						$	1,373	$	216,685	$	(192,090)			$	(6,928)	$	19,073
Net loss	Net loss	—	—			—			—			(9,452)				—				(9,452)			Net loss	—			—							—		—		(13,022)				—		(13,022)
Shares issued for options exercises		120,924	—			—			201			—				—				201
Exercise of warrants		2,954	—			(35)			40			—				—				5
Shares issued for vested restricted stock units																							Shares issued for vested restricted stock units	6,874			—							—		—		—				—		—
Share-based compensation	Share-based compensation	—	—			—			260			—				—				260			Share-based compensation	—			—							—		564		—				—		564

Balance at March 31, 2021		31,939,898	$	32		$	2,579		$	214,125		$	(157,727)			$	(6,928)			$	52,081
Balance at March 31, 2022																							Balance at March 31, 2022	32,908,922			$	33						$	1,373	$	217,249	$	(205,112)			$	(6,928)	$	6,615

The accompanying notes are an integral part of these unaudited condensed consolidated ~~condensed~~ financial statements.

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated ~~Condensed Statement~~Statements of Cash Flows

(Unaudited)

(in thousands)


		Three Months Ended March 31,					Three Months Ended March 31,
		2022		2021			2023		2022
Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Net loss	Net loss	$	(13,022)	$	(9,452)	Net loss	$	(17,330)	$	(13,022)
Adjustments to reconcile net loss to net cash used in operating activities:	Adjustments to reconcile net loss to net cash used in operating activities:					Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	Depreciation of property, plant, and equipment	286		295		Depreciation of property, plant, and equipment	671		286
Amortization of intangible and leased assets	Amortization of intangible and leased assets	312		207		Amortization of intangible and leased assets	213		312
Bad debt and other non cash receivables adjustments		30		15
Loss on disposal of net assets from discontinued operations						Loss on disposal of net assets from discontinued operations	818		30
Loss on issuance of warrants						Loss on issuance of warrants	10,424		—
Gain from change in fair value of warrants						Gain from change in fair value of warrants	(3,045)		—

Term loan discount amortization and interest accretion on debt	Term loan discount amortization and interest accretion on debt	70		2		Term loan discount amortization and interest accretion on debt	67		70

Share-based compensation expense	Share-based compensation expense	564		260		Share-based compensation expense	618		564

PPP loan forgiveness gain		—		(161)

Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Change in accounts receivable		(589)		101
Change in inventory		(1,601)		(360)
Change in prepaid expenses and other current assets		(914)		79
Change in accounts payable, accrued expenses and other liabilities		1,705		(639)
Change in deferred revenue		24		(13)
Change in operating lease liability due to cash payments		(129)		(164)
Accounts receivable						Accounts receivable	(103)		(589)
Inventory						Inventory	2,887		(1,601)
Prepaid expenses and other current assets						Prepaid expenses and other current assets	518		(914)
Accounts payable						Accounts payable	(472)		935
Accrued liabilities						Accrued liabilities	504		125
Accrued payroll and benefits						Accrued payroll and benefits	(946)		645
Deferred revenue						Deferred revenue	123		24
Operating lease liability due to cash payments						Operating lease liability due to cash payments	(157)		(129)
Net cash used in operating activities	Net cash used in operating activities	(13,264)		(9,830)		Net cash used in operating activities	(5,210)		(13,264)
Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:
Purchase of property, plant and equipment	Purchase of property, plant and equipment	(343)		(260)		Purchase of property, plant and equipment	(17)		(343)
Payment of security deposits	Payment of security deposits	(5)		—		Payment of security deposits	—		(5)
Purchase of intangible assets and other assets	Purchase of intangible assets and other assets	(504)		(452)		Purchase of intangible assets and other assets	—		(504)
Net cash used in investing activities	Net cash used in investing activities	(852)		(712)		Net cash used in investing activities	(17)		(852)
Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:

Issuance of common shares upon exercise of options and warrants		—		206

Proceeds from issuance of warrants in private placement						Proceeds from issuance of warrants in private placement	15,999		—
Payment of debt issuance costs						Payment of debt issuance costs	(380)		—
Repayment of debt						Repayment of debt	(3,000)		—
Payments on finance lease obligations	Payments on finance lease obligations	(23)		(17)		Payments on finance lease obligations	(40)		(23)

Net cash (used in) provided by financing activities		(23)		189
Net decrease in cash, cash equivalents and restricted cash		(14,139)		(10,353)
Net cash provided by (used in) financing activities						Net cash provided by (used in) financing activities	12,579		(23)
Net increase (decrease) in cash, cash equivalents and restricted cash						Net increase (decrease) in cash, cash equivalents and restricted cash	7,352		(14,139)
Cash, cash equivalents and restricted cash at beginning of period	Cash, cash equivalents and restricted cash at beginning of period	20,089		57,996		Cash, cash equivalents and restricted cash at beginning of period	12,120		20,089
Cash, cash equivalents and restricted cash at end of period	Cash, cash equivalents and restricted cash at end of period	$	5,950	$	47,643	Cash, cash equivalents and restricted cash at end of period	$	19,472	$	5,950

The accompanying notes are an integral part of these unaudited condensed consolidated ~~condensed~~ financial statements.

MEDAVAIL HOLDINGS, INC.

Condensed Consolidated ~~Condensed Statement~~Statements of Cash Flows (Continued)

(Unaudited)

(in thousands)


		Three Months Ended March 31,					Three Months Ended March 31,
		2022		2021			2023		2022
Supplemental cash flow information:						Supplemental cash flow information:
Cash paid for interest						Cash paid for interest	$	178	$	184
Supplemental noncash investing and financing activities:	Supplemental noncash investing and financing activities:					Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment	Inventory transferred to property, plant and equipment	$	429	$	58	Inventory transferred to property, plant and equipment	$	—	$	429
Property, plant and equipment transferred to intangible assets		$	—	$	36
MedCenter equipment from discontinued operations transferred to inventory for continuing operations (See Note 7)						MedCenter equipment from discontinued operations transferred to inventory for continuing operations (See Note 7)	$	4,651	$	—
Purchase of property, plant and equipment in accounts payable	Purchase of property, plant and equipment in accounts payable	$	122	$	—	Purchase of property, plant and equipment in accounts payable	$	—	$	122
Purchase of intangible assets in accounts payable	Purchase of intangible assets in accounts payable	$	326	$	—	Purchase of intangible assets in accounts payable	$	—	$	326

Lease liabilities arising from obtaining right of use assets:	Lease liabilities arising from obtaining right of use assets:					Lease liabilities arising from obtaining right of use assets:
Operating leases	Operating leases	$	205	$	279	Operating leases	$	—	$	205
Finance leases	Finance leases	$	73	$	—	Finance leases	$	231	$	73

The accompanying notes are an integral part of these unaudited condensed consolidated ~~condensed~~ financial statements.

810

MEDAVAIL HOLDINGS, INC.

Notes to Condensed Consolidated ~~Condensed~~ Financial Statements

(Unaudited)

NOTE 1 - NATURE OF OPERATIONS

MedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation, ~~formerly known as MYOS RENS Technology,~~ is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, ~~kiosk~~ and ~~drive-thru solution.~~kiosk. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter ~~facilitates~~also has the ability to facilitate live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control.

Exit of Pharmacy Services and SpotRx

On January 19, 2023, the Company announced a plan to exit the pharmacy services business to focus on its pharmacy technology business. In connection with its decision to exit the pharmacy services business, the Company initiated a reduction in force, in which employees of the pharmacy services business, representing at that time approximately 75% of the Company’s full-time employees, were terminated, effective January 18, 2023. The Company ~~also operates~~initiated the reduction in force to preserve capital and use its limited resources to pursue the pharmacy technology business.

On January 20, 2023, the Company entered into an Asset Purchase and Sale Agreement, as amended, with German Dobson CVS, L.L.C., Garfield Beach CVS, L.L.C., Longs Drug Stores California, L.L.C., Woodward Detroit CVS, L.L.C. and Holiday CVS, L.L.C., or CVS, pursuant to which the Company agreed to sell to CVS certain assets, including pharmacy records, and inventory from SpotRx orpharmacies located in Tucson and Phoenix, Arizona; Buena Park, Laguna Hills and San Fernando, California; Southfield, Michigan; and in Orlando and Tampa, Florida. The transaction closed on February 9, 2023, for a final purchase price of $2.9 million (subject to $0.1 million in fees and a $0.2 million indemnification holdback). Upon closing, the ~~Pharmacy, a full-service retail~~ pharmacy ~~utilizing~~records and inventory purchased by CVS were transferred from the SpotRx pharmacies to nearby CVS pharmacy locations.

For the year ended December 31, 2022, the pharmacy services business comprised approximately 97% of the Company’s ~~automated~~total revenues. As of December 31, 2022, inventory from SpotRx pharmacies comprised approximately $3.0 million, or 9%, of total consolidated assets. Pharmacy service business assets that were not sold to CVS have been or are expected to be primarily reabsorbed or settled, or to a lesser extent, sold or abandoned. As of March 31, 2023, the Company substantially completed its exit from the pharmacy ~~technology.~~services business.

The accounting requirements for reporting the pharmacy services business as a discontinued operation were met during the three months ended March 31, 2023. Accordingly, the condensed consolidated financial statements and notes to the consolidated condensed financial statements reflect the results of the pharmacy service business as a discontinued operation for the periods presented. See to Note 13 for additional information.

NOTE 2 - ~~GOING CONCERN~~LIQUIDITY

The condensed consolidated financial statements for the three months ended March 31, 2023 and the year ended December 31, 2022, were prepared on the basis of a going concern which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business.

On March 9, 2023, the Company entered into a Securities Purchase Agreement, or private placement (the “Offering”), of securities with certain institutional investors, or the Investors. Upon close of the transaction the Company received gross proceeds from the Offering of approximately $16.0 million, before deducting offering expenses. The Company intends to use the net proceeds from this offering to fund one-time costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related to its MedCenter technology business. Pursuant to the offering, the Company agreed to issue pre-funded warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.001 per share, or Pre-Funded Warrants, and agreed to issue Series A warrants to purchase up to an aggregate of 49,813,198 shares of common stock at an exercise price of $0.38544 per share, or Series A Warrants, to be issued following stockholder approval of the issuance of the Series A Warrants.

As of March 31, 2023, the Company had $19.5 million in cash and cash equivalents, including restricted cash, and an accumulated deficit of $257.0 million. Furthermore, net cash used in operating activities for the three months ended March 31, 2023 and 2022 was $5.2 million and $13.3 million, respectively. Since inception through March 31, 2023, the Company has continually incurred losses from its operations, which have been financed primarily by net cash proceeds from sales of common stock and warrants in private placements, sales of redeemable preferred stock and debt.

Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to ~~our~~the Company’s ability to continue as a going concern. If substantial doubt does exist ~~then~~ management should determine if there are plans in place which alleviate that doubt. ~~Since inception~~As of December 31, 2021, and through ~~March 31, 2022,~~ the Company continually incurred losses from operations which have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. Net cash used in operating activities for threenine months ended ~~March 31, 2022 and 2021 was $13.3 million and $9.8 million, respectively. As of March 31,~~September 30, 2022, the Company had ~~$5.3 million in cash and cash equivalents and an accumulated deficit of $205.1 million.~~

In April 2022, the Company completed a private placement, pursuant to which the Company received $40.0 million in gross proceeds, with an additional $10.0 million in anticipated gross proceeds to be received upon the second close expected to occur on July 1, 2022, subject to the satisfaction or waiver of the conditions to closing, before deducting placement agent commissions and other offering expenses. Additionally, the private placement included warrants, some of which may be callable at the Company’s option beginning on each of the 12 month and 24 month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. See Note 13 for further information regarding the private placement warrants.

~~Due to the Company’s significant and ongoing cash requirements to fund operations, management determined that there is~~identified substantial doubt as to the Company’s ability to continue as a going concern. ~~The Company added liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank as described in Note 8, pursuant to which~~During the ~~Company borrowed $10.0 million in aggregate initial term loans. Additionally, as referenced above,~~first quarter of 2023, the Company raised ~~$40.0 million~~capital in ~~gross proceeds through~~ a private ~~placement. There can be no assurance~~placement and reduced operating costs by exiting its pharmacy services business. As a result, after considering the Company's ongoing cash requirements to fund operations, management determined that the ~~steps management is taking will be successful. If~~Company has sufficient financial resources to continue operations through the ~~Company is unable to raise additional capital in sufficient amounts or on acceptable terms, the Company may have to significantly reduce operations or delay, scale back or discontinue development~~date of this report and ~~expansion plans. The consolidated condensed financial statements do not include any adjustments that might result~~one year from the ~~outcome~~date of ~~this uncertainty. The~~the financial statement issuance date, with no substantial doubt as to the Company’s ~~ultimate success will largely depend on continued development and deployment of MedCenter kiosks and SpotRx pharmacy operations and the~~ ability to ~~raise significant additional funding.~~continue as a going concern.

NOTE 3 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated ~~condensed~~ financial statements as of March 31, ~~2022~~2023, and for the three months ended March 31, 2023 and 2022 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial ~~information.~~information, and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated ~~condensed~~ financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated ~~condensed~~ balance sheet as of December 31, ~~2021~~2022 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements.

The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. The Company's critical accounting policies are those that are both most important to its financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company is not aware of any events or circumstances which would require update to its estimates or judgements as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, ~~2021~~2022 included in the Company's Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, which was filed with the Securities and Exchange Commission, or SEC on ~~March 29, 2022, or the 2021 Form 10-K.~~

The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-

process research and development intangible assets, and impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated condensed financial statements in the period they are deemed to be necessary.

~~Risks and uncertainties relating to COVID-19~~

The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact our clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated condensed financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results could differ from these estimates and any such differences may be material to the Company’s financial statements.April 14, 2023.

Principles of consolidation

The unaudited condensed consolidated ~~condensed~~ financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.

~~Reclassifications~~

~~During~~As noted in Note 2, as of March 31, 2023, the ~~fourth quarter of 2021, management reclassified certain operating expenses to reflect~~Company substantially completed its exit from the ~~costs attributable to~~ pharmacy operations. Specifically, certain costs were reclassified from general and administrative expenses, to pharmacy operations expenses and selling and marketing expenses. This reclassification had no impact onservices business. As a result, the Company has reported the operating results of its pharmacy services business in the loss ~~subtotal within~~from discontinued operations line in the condensed consolidated statements of operations for all periods presented. In addition, related assets and ~~comprehensive loss. The effect~~liabilities were reported as assets of discontinued operations and liabilities of discontinued operations in the condensed consolidated balance sheets for all periods presented. Unless otherwise noted, the discussion within these notes to the consolidated financial statements relates to continuing operations comprised of the ~~reclassifications within the consolidated condensed statement of operations and comprehensive loss~~pharmacy technology business. See Note 13 for ~~2021 is as follows (in thousands):~~additional information on discontinued operations.

Three Months Ended March 31, 2021
Current presentation As previously reported Change
Pharmacy operations $ 2,593 $ 1,911 $ 682
General and administrative 5,676 6,515 (839)
Selling and marketing 1,534 1,377 157
$ 9,803 $ 9,803 $ —

NOTE 4 - RECENT ACCOUNTING PRONOUNCEMENTS

Recently Issued Accounting Standards Not Yet Adopted

Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions

In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820):”- Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, or ASU 2022-03. The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements.

There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated financial statements through the reporting date.

Recently Adopted Accounting Standards

Measurement of Credit Losses on Financial Statements

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326):”- Measurement of Credit Losses on Financial Instruments”, (“or ASU ~~2016-13”),~~2016-13, supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“or ASU ~~2018-19”).~~2018-19. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, and for fiscal years beginning after December 15, 2022 for all other public business entities and private companies, with early adoption permitted. ~~This~~Effective January 1, 2023, the Company adopted ASU ~~will be effective beginning in the first quarter~~No. 2016-13. The impact of ~~our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on~~adoption of ASU 2016-13 was not material to its consolidated ~~condensed~~ financial ~~statements and related disclosures.~~

~~Recently Adopted Accounting Standards~~

~~There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.~~statements.

NOTE 5 - EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period.

The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding up to when they were exercised. After these warrants ~~were~~are exercised the related issued and outstanding common shares are included in weighted average shares outstanding:

Issuance Date

Exercise Date

~~118,228~~

~~May 9, 2018~~

~~May 10, 2021~~

~~309,698~~

~~February 11, 2020~~

~~May 10, 2021~~

~~84,911~~

~~June 29, 2020~~

~~May 10, 2021~~

~~39,208~~

~~November 18, 2020~~

~~May 10, 2021~~

19,310

November 18, 2020

Outstanding

During the three months ended March 31, ~~2022~~2023 and ~~2021,~~2022, there was no dilutive effect from stock options, restricted stock units, or RSUs, or other warrants due to the Company’s net loss position. Weighted average shares for historical periods have been adjusted for the effect of the 1.26 for 1 split on November 17, 2020. The following table sets forth the computation of basic and diluted earnings per share.

Three Months Ended March 31,
(in thousands) 2022 2021
Net loss - basic and diluted $ (13,022) $ (9,452)
Weighted average shares - basic and diluted 32,921,969 34,439,953
Net loss per share - basic and diluted $ (0.40) $ (0.27)

As of March 31, ~~2022~~2023 and ~~2021,~~2022, there were 80.2 million and 4.4 million shares of common stock, respectively, underlying outstanding options, RSUs and ~~2.5 million, respectively, of option awards outstanding~~other warrants that were not included in the diluted shares calculation because their inclusion would have been antidilutive.

NOTE 6 - FAIR VALUE MEASUREMENTS

Fair value measurements are categorized in one of the following three levels based on the lowest level input that is significant to the fair value measurement in its entirety:

Level 1 - Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 - Observable inputs other than quoted prices in active markets for identical assets or liabilities include:

a.quoted prices for similar assets or liabilities in active markets;

b.quoted prices for identical or similar assets or liabilities in inactive markets;

c.inputs other than quoted prices that are observable for the asset or liability;

d.inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3- Inputs to the valuation methodology are unobservable (i.e., supported by little or no market activity) and significant to the fair value measure.

Assets and liabilities measured at fair value on a recurring basis were as follows:

Fair Value Hierarchy
(in thousands) March 31, 2022 Level 1 Level 2 Level 3
Assets:
Cash and cash equivalents $ 5,274 $ 5,274 $ — $ —
Restricted cash 676 676 — —
Total assets $ 5,950 $ 5,950 $ — $ —


			Fair Value Hierarchy
(in thousands)	March 31, 2023		Level 1		Level 2		Level 3
Liabilities:
Warrants liabilities	$	23,378	$	—	$	—	$	23,378
Total liabilities	$	23,378	$	—	$	—	$	23,378

Fair Value Hierarchy
(in thousands) December 31, 2021 Level 1 Level 2 Level 3
Assets:
Cash and cash equivalents $ 19,689 $ 19,689 $ — $ —
Restricted cash 400 400 — —
Total assets $ 20,089 $ 20,089 $ — $ —
As of December 31, 2022, there were no assets and liabilities accounted for at fair value on a reoccurring basis.

The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to usthe Company for debt of similar risk and ~~maturities, a Level 2 input. Refer to~~maturities. See Note 8, ~~Debt,~~ for further ~~information.~~information regarding the Company’s term loan. The carrying amount of cash and cash equivalents and restricted cash approximates fair value. See Note 12, for further details regarding the Company's Warrants and fair value measurement of Warrant liabilities.

NOTE 7 - BALANCE SHEET AND OTHER INFORMATION

Restricted cash

The Company considers cash to be restricted when withdrawal or general use is legally restricted. ~~During the year ended December 31,~~In 2021 ~~the Company recovered the prior $0.06 million restricted cash balance that was held as a guarantee for certain purchasing cards. During the same period,~~ pursuant to a Loan and Security Agreement with Silicon Valley Bank (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a ~~$0.68~~$0.7 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in ~~the balance for~~ cash and cash equivalents presented in the statements of cash flows.

Accounts Receivable

Accounts receivable are primarily comprised of trade receivables presented net of allowance for doubtful accounts when estimatable and present. The Company maintains an allowance for doubtful accounts based on its assessment of the collectability of amounts owed by customers. The allowance consists of known specific troubled accounts as well as an amount based on overall estimated potential uncollectible accounts receivable based on historical experience. As of March 31, 2023, and December 31, 2022, based upon its historical collections experience, the Company had no credit risks balances which would require to be reserved as an allowance for doubtful accounts.

Inventory

The following table presents detail of inventory balances:


		March 31,		December 31,			March 31,		December 31,
(in thousands)	(in thousands)	2022		2021		(in thousands)	2023		2022
Inventory:	Inventory:					Inventory:
MedCenter hardware	MedCenter hardware	$	1,589	$	1,201	MedCenter hardware	$	8,011	$	3,331
Pharmaceuticals		2,904		2,150
Spare parts	Spare parts	595		565		Spare parts	690		663
Total inventory	Total inventory	$	5,088	$	3,916	Total inventory	$	8,701	$	3,994

~~Pharmaceutical inventory was~~MedCenter hardware recognized in pharmacy and hardware cost of products sold ~~at $7.9~~was $0.2 million and ~~$3.1~~$0.1 million during the three months ended March 31, 2023 and 2022, respectively. See Property, plant, and ~~2021, respectively. MedCenter hardware was recognized in pharmacy~~equipment below for additional details.

Prepaid expenses and ~~hardware cost of products sold at $0.1 million~~other current assets

The following table presents prepaid expenses and ~~$0.2 million during the three months ended March 31, 2022 and 2021, respectively.~~other current assets balances:


	March 31,		December 31,
(in thousands)	2023		2022
Prepaid expenses and other current assets:
Prepaid MedCenter inventory	$	1,146	$	1,359
Prepaid insurance	690		921
Other	236		289
Total prepaid expenses and other current assets	$	2,072	$	2,569

Property, plant and equipment

The following tables present property, plant and equipment balances:


		Estimated useful lives	March 31,		December 31,			Estimated useful lives	March 31,		December 31,
(in thousands)	(in thousands)		2022		2021		(in thousands)		2023		2022
Property, plant and equipment:	Property, plant and equipment:						Property, plant and equipment:
MedCenter equipment	MedCenter equipment	8 years	$	6,861	$	5,875	MedCenter equipment	8 years	$	1,531	$	7,983
IT equipment	IT equipment	1 - 3 years	2,373		2,361		IT equipment	1 - 3 years	2,002		1,908
Leasehold improvements	Leasehold improvements	lesser of useful life or term of lease	903		880		Leasehold improvements	lesser of useful life or term of lease	316		316
General plant and equipment	General plant and equipment	5 - 8 years	603		603		General plant and equipment	5 - 8 years	373		373
Office furniture and equipment	Office furniture and equipment	5 - 8 years	464		394		Office furniture and equipment	5 - 8 years	332		217
Vehicles	Vehicles	5 years	54		54		Vehicles	5 years	38		36
Construction-in-process	Construction-in-process		680		1,021		Construction-in-process		5		5
Total historical cost	Total historical cost		11,938		11,188		Total historical cost		4,597		10,838
Accumulated depreciation	Accumulated depreciation		(5,763)		(5,496)		Accumulated depreciation		(3,808)		(5,577)
Total property, plant and equipment, net	Total property, plant and equipment, net		$	6,175	$	5,692	Total property, plant and equipment, net		$	789	$	5,261

Depreciation expense of property and equipment was ~~$0.3~~$0.7 million and $0.3 million for the three months ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively. Depreciation expense included in pharmacy and hardware cost of products sold was ~~$0.03 million~~$9.0 thousand and ~~$0.05 million~~$26.0 thousand for the three months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023, as part of its strategic realignment, the Company decommissioned MedCenters operating under its discontinued retail pharmacy services business, and ~~2021, respectively.~~

reclassified out of property, plant, and equipment, and into inventory, for sale to customers, MedCenters with a net book value of $4.8 million, consisting of $6.7 million of gross book value partially offset by $1.9 million of accumulated depreciation.

Intangible assets

The following table presents intangible asset balances:


		March 31,		December 31,			March 31,		December 31,
(in thousands)	(in thousands)	2022		2021		(in thousands)	2023		2022
Gross intangible assets:	Gross intangible assets:					Gross intangible assets:
Intellectual property	Intellectual property	$	3,857	$	3,857	Intellectual property	$	3,857	$	3,857
Software	Software	5,064		4,475		Software	2,200		2,200
Website and mobile application	Website and mobile application	583		583		Website and mobile application	534		534
Total intangible assets	Total intangible assets	9,504		8,915		Total intangible assets	6,591		6,591
Accumulated amortization:	Accumulated amortization:					Accumulated amortization:
Intellectual property	Intellectual property	(3,857)		(3,857)		Intellectual property	(3,857)		(3,857)
Software	Software	(2,299)		(2,175)		Software	(1,775)		(1,749)
Website and mobile application	Website and mobile application	(583)		(583)		Website and mobile application	(534)		(534)
Total accumulated amortization	Total accumulated amortization	(6,739)		(6,615)		Total accumulated amortization	(6,166)		(6,140)
Total intangible assets, net	Total intangible assets, net	$	2,765	$	2,300	Total intangible assets, net	$	425	$	451

Amortization expense of intangible assets was ~~$0.12 million~~$26.0 thousand and ~~$0.03 million~~$2.0 thousand for the three months ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively, and are included in operating expenses.

Lessee leases

Balance sheet amounts for lease assets and leases liabilities are as follows:


		March 31,		December 31,			March 31,		December 31,
(in thousands)	(in thousands)	2022		2021		(in thousands)	2023		2022
Assets:	Assets:					Assets:
Operating	Operating	$	2,416	$	2,376	Operating	$	559	$	620
Finance	Finance	212		162		Finance	214		4
Total assets	Total assets	$	2,628	$	2,538	Total assets	$	773	$	624
Liabilities:	Liabilities:					Liabilities:
Operating:	Operating:					Operating:
Current	Current	$	626	$	599	Current	$	207	$	241
Long-term	Long-term	1,996		1,947		Long-term	413		441
Finance:	Finance:					Finance:
Current	Current	107		83		Current	37		5
Long-term	Long-term	106		80		Long-term	177		—
Total liabilities	Total liabilities	$	2,835	$	2,709	Total liabilities	$	834	$	687

The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows:

March 31, December 31,
(in thousands) 2022 2021
Finance leases:
Weighted-average remaining lease term (years) 2.2 1.5
Weighted-average discount rate 8.4 % 8.8 %
Operating leases:
Weighted-average remaining lease term (years) 4.1 4.2
Weighted-average discount rate 6.9 % 6.9 %


	March 31,		December 31,
	2023		2022
Finance leases:
Weighted-average remaining lease term (years)	4.7		0.5
Weighted-average discount rate	11.4	%	6.0	%
Operating leases:
Weighted-average remaining lease term (years)	3.5		3.6
Weighted-average discount rate	6.2	%	7.3	%

Maturities of operating leases liabilities are as ~~follows, in thousands:~~follows:


Remaining period in 2022		$	602
2023		757
(in thousands)				(in thousands)
Remaining period in 2023				Remaining period in 2023	$	211
2024	2024	617		2024	148
2025	2025	534		2025	152
2026	2026	468		2026	157
2027	2027	64		2027	37
Thereafter		—

Total lease payments	Total lease payments	3,042		Total lease payments	705
Less: present value discount	Less: present value discount	(420)		Less: present value discount	(85)
Total leases	Total leases	$	2,622	Total leases	$	620

Maturities of finance lease liabilities are as ~~follows, in thousands:~~follows:


Remaining period in 2022		$	92
2023		91
(in thousands)				(in thousands)
Remaining period in 2023				Remaining period in 2023	$	47
2024	2024	47		2024	58
2025	2025	5		2025	58
2026	2026	—		2026	58
2027	2027	—		2027	58
Thereafter		—

Total finance lease payments	Total finance lease payments	235		Total finance lease payments	279
Less: imputed interest	Less: imputed interest	(22)		Less: imputed interest	(65)
Total leases	Total leases	$	213	Total leases	$	214

Operating lease expense was ~~$0.2~~$0.1 million ~~and $0.2 million~~ for each of the three months ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively.

NOTE 8 - DEBT

The following table presents debt ~~balances at March 31, 2022 and December 31, 2021:~~balances:


		March 31,		December 31,			March 31,		December 31,
(in thousands)	(in thousands)	2022		2021		(in thousands)	2023		2022
Term loan	Term loan	10,100		10,070		Term loan	$	2,002	$	5,182
Term loan issuance costs, net	Term loan issuance costs, net	(492)		(532)		Term loan issuance costs, net	(574)		(384)
Total debt, net	Total debt, net	9,608		9,538		Total debt, net	1,428		4,798
Less short term debt	Less short term debt	—		—		Less short term debt	—		—
Long-term debt, net	Long-term debt, net	$	9,608	$	9,538	Long-term debt, net	$	1,428	$	4,798

Term loan

The Term loan bears interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% ~~(7.25%~~(12.0% at March 31, ~~2022)~~2023).

First Amendment, Consent and Default Waiver to Loan and Security Agreement

On February 10, 2023, the Company entered into the First Amendment, Consent and Default Waiver to Loan and Security Agreement or the Loan Amendment and Consent, with each of Silicon Valley Bank, a California corporation, and an authorized foreign bank under the Bank Act (Canada), and SVB Innovation Credit Fund VIII, L.P., a Delaware limited partnership, or together SVB. Among other matters, the Loan Amendment and Consent provides SVB’s consent to the sale of certain assets related to the Company’s pharmacy services business pursuant to the previously announced Asset Purchase Agreement. The Loan Amendment and Consent also provides that upon the closing of the asset sale, the Company ~~could borrow~~would pay SVB $3.4 million, which includes $0.4 million of the Final Payment (as defined in the Loan Amendment and Consent) and prepayment of $3.0 million of Term Loan Advances (as defined in the Loan Amendment and Consent), with SVB waiving the prepayment premium due on all Term Loan Advances prepaid by the Company prior to February 10, 2023. The Loan Amendment and Consent also includes SVB's waiver of any legal action or enforcement of rights and remedies with respect to certain specified defaults arising prior to February 10, 2023.

On February 10, 2023, in connection with the Loan Amendment and Consent, the Company issued warrants, or the SVB Warrants, to SVB for the purchase of up to an ~~additional $20.0 million~~aggregate of 200,366 shares of common stock at a per share exercise price of $0.3274, with an expiration date of February 10, 2035. The number of shares and the exercise price are subject to adjustment as set forth in ~~aggregate term loans on or before April 30, 2022, however this option was not used and expired.~~the SVB Warrants. See Note 12.

SVB Letter Agreement

On March 13, 2023, the Company was informed by SVB that the Company was still bound by the terms, conditions, and covenants of the Company’s Loan and Security Agreement with SVB, or the Loan Agreement, and the Loan Amendment and Consent. On March 29, 2023, the

Company entered into a Letter Agreement, or Letter Agreement, with each of (a) Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB Successor, in its capacity as administrative agent and collateral agent, (b) SVB Successor, as a lender, and (c) SVB Innovation Credit Fund VIII, L.P., or SVB Capital, as a lender, and obtained a waiver for any event of default occurring prior to March 29, 2023, to include the year ended December 31, 2022. The Letter Agreement also amends the Loan Agreement to provide that the Company is only required to maintain on deposit at SVB Successor or its affiliates, at least 50% of the aggregate dollar value of all of the Company accounts at all financial institutions.

As of March 31, 2023, the Company had approximately $9.8 million on deposit with SVB Successor and $9.7 million on deposit with another financial institution and was in compliance with all required covenants of the Loan Agreement. The Company continues to monitor the circumstances surrounding SVB and does not anticipate such circumstances will have a material impact on the Company's financial condition, operations, or on the Loan Agreement with SVB Successor. As of the date of filing this Quarterly Report on Form 10-Q, the Company has full access to and control over all of its cash, and cash equivalents across all financial institutions.

NOTE 9 - INCOME TAXES

The Company incurred minimal income tax expense for the three months ended March 31, 2023 and 2022, due to ongoing losses and minimum state income tax obligations. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses.

As of March 31, 2023 and December 31, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.

~~On March 11, 2021, the U.S. federal government enacted the American Rescue Plan Act of 2021, which did not have a material impact on our benefit for income taxes.~~

NOTE 10 - COMMITMENTS AND CONTINGENCIES

~~Legal~~Litigation

~~Following MYOS Rens Technology Inc.’s, or MYOS’s~~The Company is and, ~~MedAvail, Inc.’s, or MAI's, announcement~~from time to time may in the future become, involved in legal proceedings, claims and litigation in the ordinary course of business. The Company has become subject to certain demands, and claims from former employees relating to the reduction in force the Company implemented in connection with the restructuring of the ~~execution~~company and the disposition of its pharmacy services business. The Company intends to vigorously defend itself against such pending and threatened actions. The Company cannot determine a reasonable estimate of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Courtmaximum possible loss or range of loss for pending or threatened matters given that they are at various stages of the ~~State~~litigation process and each case is subject to the inherent uncertainties of ~~New York, County~~litigation. In management’s opinion, based on currently available information, any potential loss resulting from the resolution of ~~New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020),~~these matters is not expected to have a material adverse effect on the Company’s results of operations, financial position, or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation.

The Demands and the Complaints that comprise the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties.

MYOS and MAI believe that the claims asserted in the Litigation are without merit, and believe that the Form S-4 Registration Statement disclosed all material information concerning the Merger and no supplemental disclosure is required under applicable law. However, in order to avoid the risk of the Litigation delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, MYOS determined to voluntarily supplement the Form S-4 Registration Statement as described in the Current Report on Form 8-K on November 2, 2020. Subsequently, the Nevada Complaint and the New York Complaint were voluntarily dismissed. The remainder of the Litigation remains outstanding. MYOS and MAI specifically deny all allegations in the Litigation and/or that any additional disclosure was or is required.cash flows.

NOTE 11 - SHARE-BASED COMPENSATION ~~AND WARRANTS~~

Share-based compensation

The following table presents the Company's expense related to share-based compensation, in thousands:

Three Months Ended March 31,
2022 2021
Share-based compensation $ 564 $ 260


	Three Months Ended March 31,
	2023		2022
Share-based compensation	$	618	$	564

~~The share-based compensation expense for the three months ended March 31, 2022, included $0.03 million from 2020 ESPP expense.~~ Expense remaining to be recognized for unvested option awards from the 2012, 2018, 2020 and ~~2020~~2022 plans as of March 31, ~~2022~~2023, was ~~$2.7~~$1.8 million, which will be recognized on a weighted average basis over the next ~~3.2~~2.6 years. Expense remaining to be recognized for unvested RSU awards as of March 31, 2023, was ~~$2.7~~$1.6 million, which will be recognized on a weighted average basis over the next ~~2.7~~1.9 years.

1518

The following table presents the Company's outstanding option awards activity during the three months ended March 31, ~~2022:~~2023:


(in thousands, except for share and per share amounts)	(in thousands, except for share and per share amounts)	Number of Awards	Weighted Average Exercise Price		Weighted Average Share Price on Date of Exercise	Weighted Average Fair Value		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value		(in thousands, except for share and per share amounts)	Number of Awards	Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, beginning of period	Outstanding, beginning of period	2,848,903	$	2.78		$	1.44	0	$	31	Outstanding, beginning of period	4,399,741	$	1.88	$	1.14		$	—
Granted	Granted	1,749,015	1.18			0.85			—		Granted	—	—		—			—
Exercised/Released	Exercised/Released	—	—			—			—		Exercised/Released	—	—		—			—
Expired	Expired	(117,730)	2.11			1.15			—		Expired	—	—		—			—
Forfeited	Forfeited	(127,617)	3.18			1.66			—		Forfeited	(66,302)	1.37		0.83			—
Outstanding, end of period	Outstanding, end of period	4,352,571	$	2.15		$	1.21	8.54	$	40	Outstanding, end of period	4,333,439	$	1.89	$	1.15	8.05	$	—
Vested and exercisable, end of the period	Vested and exercisable, end of the period	1,710,753	2.17			1.07		6.88	—		Vested and exercisable, end of the period	2,079,894	2.23		1.22		7.03	—
Vested and unvested exercisable, end of the period	Vested and unvested exercisable, end of the period	1,710,753	2.17			1.07		6.88	—		Vested and unvested exercisable, end of the period	2,079,894	2.23		1.22		7.03	—
Vested and expected to vest, end of the period	Vested and expected to vest, end of the period	4,095,070	2.16			1.21		8.47	38		Vested and expected to vest, end of the period	4,180,949	1.91		1.15		8.02	—

~~During the three months ended March 31, 2022, the Company granted approximately 1.2 million restricted stock units or RSUs to employees with a weighted average fair value of $1.20 per~~The following table present outstanding RSU ~~and total aggregate intrinsic value of $1.4 million. 12,048 RSUs vested and 26,074 RSU's were forfeited~~awards activity during the three months ended March 31, ~~2022.~~2023:


	Number of Awards	Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Unvested outstanding, beginning of period	2,376,554	$	—	$	1.31
Granted	—	$	—	$	—
Exercised/Released	—	$	—	$	—
Cancelled/Forfeited	(763,380)	$	—	$	0.87
Expired	—	$	—	$	—
Unvested outstanding, end of period	1,613,174	$	—	$	1.40	14.14
Vested, outstanding shares	—	$	—	$	—

As of March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, there was an aggregate of ~~2.1~~2.7 million and ~~3.4~~2.3 million shares of common stock, respectively, available for grant under the 2020 Plan. As of March 31, 2023 and December 31, 2022, there was an aggregate of 1.1 million and 0.2 million shares of common stock, respectively, available for grant under the 2022 Inducement plan.

NOTE 12 - WARRANTS

Equity Warrants

During the twelve months ended December 31, 2022, 18.8 million warrants were issued at the first closing of a private placement in April 2022 ~~the Company adopted the MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan or the Inducement Plan. The Inducement Plan reserved 1,500,000 shares~~with a fair value of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 8, 2022, the Company issued inducement awards to employees that included options to purchase 426,500 shares of Company common stock,$9.2 million, a 5 years term and ~~426,500 RSUs. The inducement stock options have~~ an exercise price per share of ~~$1.96, and 25%~~$1.25. An additional 4.7 million warrants were issued at a second closing of the ~~shares vest on the one year anniversary~~private placement in July 2022 with a fair value of ~~the date that employment commenced,~~$4.5 million, a 5 years term and an ~~additional one forty-eighth (1/48th)~~exercise price per share of $1.25.

No warrants were exercised or expired during the ~~shares vest monthly thereafter. The inducement RSUs vest at one-third (1/3rd) of~~three months ended March 31, 2023, or twelve months ended December 31, 2022. These warrants met the ~~shares on the first, second~~equity classification requirements and ~~third yearly anniversaries of March 1, 2022.~~therefore are classified in our stockholders' equity.

~~Warrants~~SVB warrants

During the three months ended March 31, ~~2022~~2023, as part of the First Amendment to the Loan and Security Agreement with Silicon Valley Bank (see Note 8), the Company issued 200,366 common stock warrants to the lenders. Upon grant date, the fair value of the warrants was $57 thousand, measured using the Black Scholes Option Pricing model. There was no material change in fair value of these warrants through March 31, 2023.

The SVB Warrants met equity classification requirements under ASC 815 - Derivative and Hedging, specifically due to the warrants having a limit on the number of shares the entity will be required to deliver upon exercise and the warrants not including cash-settled top-off or make-

whole provisions, as well as, other conditions. As such, the SVB warrants met the equity classification requirements and are classified in the Company's shareholder' equity.

The key input assumptions utilized in the valuation of the SVB Warrants were as follows:


	Grant date	March 31, 2023
Market price	$0.32	$0.29
Exercise price	$0.32	$0.32
Term (Years)	12	11.7
Volatility	85%	85%
Risk Free Rate	3.68%	3.60%

Liability warrants

The following table presents liability warrants:


	March 31,	December 31,
(in thousands)	2023	2022
Pre-Funded Warrants	14,295	—
Series A Warrants	9,083	—
	23,378	—

Private placement

On March 9, 2023, the Company entered into a Securities Purchase Agreement for a private placement of securities with certain institutional investors, or the Investors. Pursuant to the terms of the Offering, the Company agreed to issue Pre-Funded Warrants upon closing at a price of $0.3212 per underlying share, and Pre-Funded Warrants are exercisable into shares of common stock at an exercise price of $0.001 per share. The number of Pre-Funded Warrants exercisable is limited by the Nasdaq 19.99% cap based on the shares of Common Stock outstanding; until the Company's stockholders approve issuing Common Stock in excess of the Nasdaq 19.99% cap at the Company's annual shareholder meeting to be held June 14, 2023. Additionally, the Company provided the Investors with Series A Warrants with an exercise price of $0.385440 per share, that are not exercisable until the stockholders approve the Company to issue Common Stock in excess of the Nasdaq 19.99% cap.

The Pre-Funded Warrant shares are exercisable for an aggregate of up to 49,813,198 shares of common stock, and the Series A Warrants will be exercisable for an aggregate of up to 49,813,198 shares of common stock. Upon close of the transaction on March 13, 2023, the Company received gross proceeds from the Offering of approximately $16.0 million, before deducting Offering expenses. The Company intends to use the net proceeds from the Offering to fund costs associated with restructuring, repay outstanding debt, and finance its growth initiatives related ~~party~~to its MedCenter technology business.

Upon grant, the fair value of the Pre-Funded Warrants and Series A Warrants was $15.9 million and $10.5 million, respectively. The Company recorded the $10.4 million difference between the Offering proceeds and grant date fair value as a loss on issuance of warrants ~~outstanding~~in the statement of operations and comprehensive loss. The fair values of the awards were measured using the Black Scholes Option Pricing model as of the grant date.

The key input assumptions utilized in the valuation of the Pre-funded Warrants were as follows:


	Grant date	March 31, 2023
Market price	$0.32	$0.29
Exercise price	$0.001	$0.001
Term (Years)	12	11.7
Volatility	85%	85%
Risk Free Rate	3.70%	3.67%

The key input assumptions utilized in the valuation of the Series A Warrants were as follows:


	Grant date	March 31, 2023
Market price	$0.32	$0.29
Exercise price	$0.39	$0.39
Term (Years)	5	4.9
Volatility	85%	85%
Risk Free Rate	3.68%	3.60%

The fair values of the Pre-Funded Warrants and Series A Warrants decreased $1.6 million and $1.4 million, respectively, during the three months ended March 31, ~~2022.~~2023; which is included in the gain from change in fair value of warrants on the statement of operations and comprehensive loss.

NOTE 1213 - ~~REVENUE AND SEGMENT REPORTING~~DISCONTINUED OPERATIONS

~~Operating segments are~~As discussed in Note 1 – Nature of Operations – the ~~individual operations that~~exit of our pharmacy services business was substantially completed as of March 31, 2023. The pharmacy services business was previously a reportable segment and the ~~chief operating decision maker,~~exit represents a strategic shift in the Company going forward. Accordingly, with the sale or ~~CODM, who is our chief executive officer, reviews for purposes~~disposition of ~~assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The~~its retail pharmacy assets and exit of the pharmacy services business, this transaction meets the accounting requirements for reporting as discontinued operations under ASC 205-20-50 for all periods presented.

The following table summarizes the major income and expense line items from discontinued operations as reported in the condensed consolidated statements of operations and comprehensive loss:


	Three Months Ended March 31,
(in thousands)		2023		2022
Revenue:
Pharmacy revenue		$	3,834	$	8,849
Total revenue		3,834		8,849
Cost of products sold and services:
Pharmacy cost of products sold		3,581		8,481
Total cost of products sold and services		3,581		8,481
Operating expense:







Pharmacy operations		1,726		3,720
General and administrative		570		1,563
Selling and marketing		845		2,205
Research and development		—		235

Total operating expense		3,141		7,723
Operating loss		(2,888)		(7,355)
Loss from sale and disposition of net assets, and reorganization expenses, net		(1,885)		—

Interest expense		1		(3)


Loss from discontinued operations		$	(4,772)	$	(7,358)

Cash provided by operating activities by the pharmacy ~~technology operating segments both engage~~services business totaled $3.5 million and $0.1 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Cash used in ~~different business~~investing activities from the pharmacy services business totaled totaled $0.02 million and $0.35 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Cash used in financing activities from the pharmacy services business totaled totaled $0.03 million and $0.02 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Depreciation and amortization expense of the pharmacy services business totaled totaled $0.75 million and $0.48 million for the three months ended March 31, 2023 and March 31, 2022, respectively. The condensed consolidated statements of cash flows included $0.8 million loss on disposal of net assets from discontinued operations, which ~~they earn revenues~~comprised of losses related to net realizable value adjustments to right of use assets related to leases and ~~incur expenses.~~

~~The Company has the following 2 reportable segments:~~

~~Retail Pharmacy Services Segment~~

~~Retail Pharmacy Services segment revenue consists~~prepaid assets, and abandonment of ~~products sold directly~~certain property, plant, and equipment related to consumers at the point of sale. MedAvail recognizes retail pharmacy revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts.

~~Pharmacy Technology Segment~~

The Pharmacy Technology Segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sumour discontinued operations.

1621

payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements.

The following table ~~presents revenue and costs~~summarizes the major classes of ~~products sold and services by segment, in thousands:~~

Retail Pharmacy Services Pharmacy Technology Total
Three Months Ended March 31, 2022
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue $ 8,849 $ — $ 8,849
Hardware — 56 56
Subscription — 109 109
Total pharmacy and hardware revenue 8,849 165 9,014
Service revenue:
Software integration — — —
Software — 48 48
Maintenance and support — 32 32
Installation — 6 6
Professional services and other — 14 14
Total service revenue — 100 100
Total revenue 8,849 265 9,114
Cost of products sold and services 8,482 131 8,613
Segment gross profit $ 367 $ 134 501
Operating Expense:
Pharmacy operations 3,929
General and administrative 6,535
Selling and marketing 2,313
Research and development 493
Total operating expense 13,270
Operating loss $ (12,769)

Retail Pharmacy Services Pharmacy Technology Total
Three Months Ended March 31, 2021
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue $ 3,418 $ — $ 3,418
Hardware — 241 241
Subscription — 122 122
Total pharmacy and hardware revenue 3,418 363 3,781
Service revenue:
Software integration — — —
Software — 33 33
Maintenance and support — 31 31
Installation — 16 16
Professional services and other — 166 166
Total service revenue — 246 246
Total revenue 3,418 609 4,027
Cost of products sold and services 3,329 378 3,707
Segment gross profit $ 89 $ 231 320
Operating Expense:
Pharmacy operations 2,593
General and administrative 5,676
Selling and marketing 1,534
Research and development 168
Total operating expense 9,971
Operating loss $ (9,651)

~~The following table presents~~ assets and liabilities ~~by segment, in thousands:~~

Retail Pharmacy Services Pharmacy Technology Corporate Total
March 31, 2022
Assets $ 16,323 $ 6,661 $ 4,708 $ 27,692
Liabilities $ 6,705 $ 4,183 $ 10,189 $ 21,077
December 31, 2021
Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143
Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070

~~The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based~~of the retail pharmacy business as reported on the ~~physical location of the assets, in thousands:~~condensed consolidated balance sheets:

March 31, December 31,
2022 2021
Long-lived assets:
United States $ 8,383 $ 7,675
Canada 420 555
Total long-lived assets $ 8,803 $ 8,230


(in thousands)	March 31, 2023		December 31, 2022
Carrying amounts of major classed of assets included as part of discontinued operations:
Accounts receivable, net	$	2,065	$	1,804
Prepaid expenses and other current assets	14		95
Inventories	—		2,943
Total current assets from discontinued operations	$	2,079	$	4,842

Intangible assets, net	$	—	$	14
Property plant and equipment, net	—		1,194
Right-of-use assets	998		1,461
Other assets	168		168
Total long-term assets from discontinued operations	$	1,166	$	2,837

Total long-term assets from discontinued operations
Accounts payable	$	290	$	857
Accrued liabilities	1,105		642
Accrued payroll and benefits	28		834
Current portion of lease obligations	462		461
Total current liabilities from discontinued operations	$	1,885	$	2,794

Long-term portion of lease obligations	$	1,015	$	1,128
Total long-term liabilities from discontinued operations	$	1,015	$	1,128

NOTE 1214 - SUBSEQUENT EVENTS

Reduction in Force

On ~~March 30, 2022,~~April 27, 2023, the Company entered into a Securities Purchase Agreement, or Purchase Agreement, with certain purchasers thereto, or the Investors. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investorscompleted an additional reduction in ~~a private placement, or the Private Placement, up to 47.1 million shares, or the Shares,~~force, in which approximately 27% of the Company’s ~~Common Stock,~~full-time employees at that time, were terminated, effective April 28, 2023. The Company notified the employees of their termination on April 27, 2023. The reduction in force is in connection with the Company’s continued efforts to streamline operations and achieve cost savings while focusing on its pharmacy technology business. The Company may incur additional expenses not currently contemplated due to ~~issue warrants, or~~events associated with the ~~Warrants, to purchase up to 23.5 million shares of Common Stock, or Warrant Shares.~~reduction in force. The ~~Shares and the Warrants were or will be sold at 2 closings as further described below, at a price per share of $1.0625.~~

~~Each Investor purchasing Shares in the Private Placement was or will also be issued a Warrant to purchase~~changes that number of Warrant Shares equal to 50% of the number of Shares purchased under the Purchase Agreement by such Investor. The Warrants have a per share exercise price of $1.25 and will be exercisable by the holder at any time on or after the issuance date of the Warrant for a period of five years. If the Warrants were exercised in full by the Investors, the Company ~~would receive additional gross proceeds of up~~expects to ~~$29.4 million. In addition,~~incur in connection with the ~~Warrant terms provide the Company with a call option to~~reduction in force the Warrant holders to exercise up to two-thirds of the warrant shares subject to each Warrant, with one-third of the Warrant Shares being callable beginning on each of the 12 month and 24 month anniversaries of the Warrant issuance dates, in each case until the expiration of the Warrants,are estimates and subject to ~~the satisfaction~~a number of certain pricing conditions relating to the trading of the Company’s shares. If the Company were to exercise the contingent call options, approximately $19.6 million in additional equity could be raised.

~~On April 4, 2022, the first closing of the Private Placement occurred, in which 37.6 million shares of Common Stock for $40.0 million in gross proceeds,~~assumptions, and Warrants exercisable for up to 18.8 million Warrant Shares were sold and issued by the Company, and pursuant to which the Company received $40.0 million in gross proceeds, before deducting placement agent commissions and other offering expenses. A second and final closing is expected to occur in July 2022, subject to the satisfaction or wavier of certain conditions to closing, pursuant to which the Company shall sell and issue, and the Investors shall purchase, an additional 9.4 million shares of Common Stock for $10.0 million in additional gross proceeds and Warrants exercisable for up to 4.7 million Warrant Shares.

actual results may differ materially.

1922

Item 2. ~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~Management's Discussion and Analysis of Financial Condition and Results of Operations

~~You should read the~~The following discussion should be read in conjunction with our audited historical condensed consolidated ~~condensed~~ financial statements for the year ended December 31, ~~2021,~~2022 which are included in the Annual Report on Form 10-K, filed with the Securities and Exchange Commission on ~~March 29, 2022,~~April 14, 2023, and our unaudited condensed consolidated ~~condensed~~ financial statements and accompanying footnotes for the three months ended March 31, ~~2022~~2023, included ~~elsewhere in~~Part I, Item 1., of this Quarterly Report on Form 10-Q.

This ~~Management's~~quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains statements that are ~~forward-looking.~~forward-looking regarding future events and our future results subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements.

All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expect. These statements are based on current expectations and assumptions that are subject to risks, uncertainties and other factors. Actual results could differ materially because of the factors discussed ~~below or~~above and elsewhere in this Quarterly Report on Form 10-Q. See Part II, Item 1A. "Risk Factors" of this Quarterly Report on Form 10-Q, and Part I, Item 1A. "Risk Factors" of ~~the 2021~~our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. Unless otherwise indicated or the context otherwise requires, references herein to “MedAvail,” “MedAvail Holdings,” “we,” “us,” “our,” and the “Company” refers to MedAvail Holdings, Inc. and its subsidiaries.

Overview

We are a technology-enabled ~~retail~~ pharmacy technology ~~and~~ services company, weand have developed and commercialized an innovative self-service pharmacy, mobile application, ~~kiosk,~~ and ~~drive-thru solution.~~kiosk. Through our full-stack pharmacy technology platform, and personal one-on-one service, we bring pharmacy-dispensing capability to the point of care, resulting in lower costs, higher patient satisfaction, improved medication adherence, and better health outcomes.

We offer a unique, pharmacy technology solution which is anchored around our core technology called the MedAvail MedCenter™, or the MedCenter. The MedCenter enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and any other location where onsite prescription dispensing is desired. The MedCenter establishes an audio-visual connection to a live pharmacist enabling remote prescription drug dispensing to occur directly to a patient while still providing real-time supervision by a pharmacist. ~~Although~~

Currently, our ~~technology platform has broad application, we are currently focused on serving high-value Medicare members in the United States of America, or U.S.~~

~~We currently deploy the MedCenter solution through two distinct commercialization channels. First, we own~~primary and operate a full retail pharmacy business in the U.S. under the name SpotRx™, or SpotRx. The SpotRx pharmacy business is structured as a hub-and-spoke model where a central pharmacy supports and operates MedCenter kiosks embedded in medical clinics, usually in close proximity to the central pharmacy. The secondonly commercialization channel is athe direct ‘sell-to’ model, whereby we sell or lease the MedCenter hardware technology and ~~subscriptions for~~provide recurring, one-time, or on demand services related to the ~~associated software~~MedCenter directly to large healthcare providers and retailers for use within their own pharmacy operations. We deploy the MedCenter solution currently to locations to include, but not limited to, urgent care and emergency medical facility locations, in clinic locations of large healthcare providers, and University campuses.

The MedCenter kiosk works in tandem with our Remote Dispensing System®, or the Remote Dispensing System, which consists of customer-facing software for remote ordering of medications for pick-up at a ~~MedCenter, or next day home delivery.~~MedCenter. Supporting our MedCenter kiosks and Remote Dispensing System is our back-end MedPlatform® Enterprise Software, or the MedPlatform Enterprise Software, which controls dispensing and MedCenter ~~monitoring;~~monitoring, and supporting Pharmacy Management System ~~software, which allows connection to our supporting team of pharmacists and kiosk administrators.~~software.

Our kiosks come in ~~two models:~~one model: the M4 ~~MedCenter and the M5~~ MedCenter. The M4 MedCenter ~~kiosk~~ is designed to fit in waiting rooms, hallways, and lobbies. ~~The M5 MedCenter is~~

Discontinued Operations

On January 19, 2023, we announced our plan to exit the retail pharmacy services business, or the “Pharmacy Services Business”, to focus on our Pharmacy Technology services. In connection with our exit from the Pharmacy Services Business, we hired a ~~larger kiosk designed~~broker and negotiated the sale of certain related pharmacy assets. Our operations following the exit from the Pharmacy Services Business consist solely of our Pharmacy Technology services. On April 6, 2023, we announced that we had completed the transactions contemplated by the Asset Purchase Agreement, including the disposition of the specific assets therein, on February 10, 2023. As of March 31, 2023, we have substantially completed our exit from the Pharmacy Services Business.

Prior to Discontinued Operations, during the three months ended March 31, 2023, we had two reportable segments: retail pharmacy services and pharmacy technology services. As a result of the retail pharmacy services business exit, the Company met the requirements of ASC 205-20, to report the results of the retail pharmacy services business as a ~~full~~discontinued operation. Accordingly, the operating results for the retail pharmacy ~~replacement with~~services business have therefore been reclassified as a discontinued operation within these condensed consolidated financial statements. As such, unless otherwise noted, the ~~ability~~discussion of our operating results, Results of Operations, and Liquidity relate to ~~serve 3-4 customers simultaneously. It can also be configured for drive through dispensing, similar to bank ATM drive through lanes.~~

~~Traditional retail pharmacies are built around a physical store front. In order to dispense medication, these stores must have a pharmacist onsite~~continuing operations comprised of only our pharmacy technology business for all hours of operation. Many pharmacies have reduced hours of operation based on customer purchasing patterns in order to contain labor cost, which results in further reduced consumer access. Furthermore, retail pharmacy wait times are typically 30 to 60 minutes or more, causing substantial delays for the consumer. During the COVID-19 pandemic, many people are looking to minimize the amount of physical contact that can lead to further disease contraction, especially for those most vulnerable, such as the elderly or those with compromised immune systems. Consequently, some patients are foregoing filling their prescribed medications, leading to declining health, increased healthcare costs and increased morbidity.periods presented.

Components of Operating Results for the Three Months Ended March 31, ~~2022~~2023

We have never been profitable and wehave incurred operating losses in each year since inception. Our net losses were ~~$13.0~~$17.3 million and ~~$9.5~~$13.0 million for the three months ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively. As of March 31, ~~2022,~~2023, we had an accumulated deficit of ~~$205.1~~$257.0 million. Substantially all of our operating losses resulted from expenses incurred in connection ~~with building out our retail pharmacy services operating footprint and from~~ general and administrative costs associated with our ~~operations.~~operations

We expect to incur ~~significant~~ additional expenses and operating losses ~~for the foreseeable future~~ as we ~~initiate and~~ continue ~~the~~our technology development, ~~deployment~~redeployment of our ~~MedCenter technology~~MedCenters and ~~adding personnel~~right size expenses necessary to operate ~~as a public company with rapidly growing~~

retail pharmacy operations in the United States. In addition, operating as a publicly traded company involves the hiring of additional financial and other personnel, upgrading our financial information systems and incurring costs associated with operating as a public company. We expect that our operating losses will decrease and turn positive as we execute our growth strategies ~~within~~and focus on our ~~operating segments.~~Med Center technologies. If our management accelerates deployment into new states, operating losses could increase in the near-term, as we grow and scale our ~~operations; we expect operating performance to turn positive once each state reaches sufficient scale in sales volume.~~operations.

As of March 31, ~~2022,~~2023, we had cash and cash equivalents of ~~$5.3~~$18.8 million. We will continue to require additional capital to continue our pharmacy technology development and commercialization activities ~~and build out our pharmacy operations~~ to serve our growing customer base. ~~Accordingly, in November 2020~~In April and ~~April~~July 2022, and March 2023, we completed the sale of additional equity through a private placement ~~funding,~~financings, where we raised ~~$83.9~~$40.0 million and ~~$40.0~~$16.0 million in gross proceeds, respectively. Additionally, in June 2021 we ~~entered into~~added to our liquidity resources through a senior secured term loan ~~and borrowed~~with Silicon Valley Bank, or SBV, of $10.0 million, of which we have repaid $8.0 million. ~~We expect to raise additional capital to continue funding operations.~~As of March 31, 2023, we have an outstanding principal balance of $2.0 million under the term loan. The amount and timing of future funding requirements will depend on many factors, including the pace and results of our growth strategy and capital market conditions. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop product candidates.

Results of Operations for the Three Months Ended March 31, 2023

Pharmacy technology revenue

Hardware revenue

We ~~have two reportable segments: Retail Pharmacy Services~~develop and ~~Pharmacy Technology. These reportable segments are generally defined by how we execute our go-to-market strategy to sell products and services.~~

~~Overview of Retail Pharmacy Services Segment~~

The Retail Pharmacy Services operating segment operates as SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing our automated pharmacy technology, primarily servicing Medicare patients in the United States. In operating SpotRx, we employ the pharmacy team, purchase the medications, and deploy our proprietary technology, the MedCenter, directly into the Medicare-focused clinics. This is an end-to-end turnkey solution.

~~Overview of Pharmacy Technology Segment~~

~~MedAvail Technologies develops and commercializes~~commercialize the MedCenter for direct sale or subscription lease to third-party customers, including some of the world’s largest healthcare providers and systems, as well as large retail chains that provide full retail-pharmacy services using our technology.

~~Results of Operations for the Three Months Ended March 31, 2022~~

~~Revenue – Retail Pharmacy and~~ Hardware ~~and Service~~

~~Retail pharmacy and hardware revenue~~

~~Retail pharmacy~~ revenue from the Retail Pharmacy Services segment are derived from sales of prescription medications and over-the-counter products to patients. Medications are sold and delivered by various methods including dispensing product directly from the MedCenter, patient pick up at MedAvail’s SpotRx pharmacy locations or home delivery of medications to patient residences. Hardware sales from the pharmacy technology segment areis derived from either ~~the~~ sales or subscription leases of the MedCenter to customers.

Service revenue

~~Services~~

Service revenue ~~from the Pharmacy Technology Segment~~ is derived from ~~installation~~recurring subscription revenue from software licensing, platform and ~~support~~software hosting, and software and hardware maintenance; and one-time or on demand service revenue from initial installations, and professional services such as training, pharmacy set-up, and consulting services.

Revenue


		Three Months Ended March 31,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
Pharmacy and hardware revenue:		(in thousands)
Retail pharmacy revenue		$	8,849	$	3,418	$	5,431	159	%
Hardware		56		241		(185)		(77)	%
Subscription		109		122		(13)		(11)	%
Total pharmacy and hardware revenue		9,014		3,781		5,233		138	%
											(in thousands)
Hardware and subscription revenue:										Hardware and subscription revenue:

Hardware revenue										Hardware revenue	$	256	$	56	$	200	357	%
Subscription revenue										Subscription revenue	48		109		(61)		(56)	%
Total hardware and subscription revenue										Total hardware and subscription revenue	304		165		139		84	%
Service revenue:	Service revenue:									Service revenue:
Software integration		—		—		—		—	%

Software	Software	48		33		15		45	%	Software	94		48		46		96	%
Maintenance and support	Maintenance and support	32		31		1		3	%	Maintenance and support	56		32		24		75	%
Installation	Installation	6		16		(10)		(63)	%	Installation	67		6		61		1017	%
Professional services and other	Professional services and other	14		166		(152)		(92)	%	Professional services and other	99		14		85		607	%
Total service revenue	Total service revenue	100		246		(146)		(59)	%	Total service revenue	316		100		216		216	%
Total revenue	Total revenue	$	9,114	$	4,027	$	5,087	126	%	Total revenue	$	620	$	265	$	355	134	%

During the three months ended March 31, ~~2022, retail pharmacy~~2023, hardware and ~~hardware~~subscription revenue increased ~~$5.2~~$0.1 million to ~~$9.0~~$0.3 million compared to the same period in ~~2021.~~2022. The ~~$5.2~~$0.1 million increase was primarily due to a ~~$5.4~~$0.2 million increase ~~from volume growth in prescription revenue at existing sites and additional sites launched in Florida and Michigan throughout 2021 and continuing into 2022,~~MedCenter sales whereby 3 more MedCenters were sold over the same prior year period, partially offset by ~~the~~$0.1 million decrease in ~~hardware revenue from the first quarter 2021.~~

~~During the three months ended March 31, 2022, service revenue decreased $0.15 million to $0.10 million compared to the same period in 2021.~~

~~Cost of Products Sold and Services~~

~~Retail pharmacy and hardware cost of products sold~~

~~Cost of products sold consists primarily of prescription medications, and other over-the-counter health products; and costs associated with MedCenters sold to third-party customers.~~

~~Service costs~~

~~Service costs consists primarily of costs incurred to install and maintain MedCenters at third-party customer locations.~~

~~Costs of Products and Services~~

Three Months Ended March 31, 2022 vs. 2021
2022 2021 Amount Change % Change
Retail pharmacy and hardware cost of products sold: (in thousands)
Prescription drugs $ 7,856 $ 3,060 $ 4,796 157 %
Shipping 625 270 355 131 %
Hardware 56 150 (94) (63) %
Depreciation 26 46 (20) (43) %
Total retail pharmacy and hardware cost of products sold 8,563 3,526 5,037 143 %
Service costs:
Professional services 1 142 (141) (99) %
Maintenance and support services 45 28 17 61 %
Installation services 4 11 (7) (64) %
Total service costs 50 181 (131) (72) %
Total cost of products sold and services $ 8,613 $ 3,707 $ 4,906 132 %
subscription lease revenue.

2224

During the three months ended March 31, ~~2022, retail pharmacy and hardware cost of products sold~~2023, service revenue increased ~~$5.0~~$0.2 million to ~~$8.6~~$0.3 million compared to the same period in ~~2021. The increase was~~2022 primarily due to ~~costs associated with volume growth in prescription~~increased services provided as a result of increased MedCenter sales at existing sites and additional sites launched in Florida and Michigan throughout 2021 and continuing into 2022. Shipping costs, related to our home delivery service via third-party courier, increased $0.4 millionduring the three months ended March 31, 2023, compared to the same ~~period in 2021.~~prior year period..

As a result of the pharmacy services business exit, the Company met the requirements of ASC 205-20, to report the results of the retail pharmacy services business as a discontinued operation. Accordingly, the revenue results for the pharmacy services business have therefore been reclassified as a discontinued operations within these condensed consolidated financial statements.

Pharmacy technology cost of products sold and services

Hardware costs of products

Hardware cost of products sold consists primarily of costs associated with building and customization of MedCenters sold to third-party customers.

Service costs

Service costs consists primarily of installation, integration, relocation, consumable, and maintenance cost of MedCenters at third-party customer locations, as well as related hosting and software costs.

Costs of Products sold and Services


	Three Months Ended March 31,				2023 vs. 2022
	2023		2022		Amount Change		% Change
	(in thousands)
Hardware cost of products sold:


Hardware	$	210	$	56	$	154	275	%
Depreciation	35		25		10		40	%
Total Hardware cost of products sold	245		81		164		202	%
Service costs:
Professional services	14		—		14		—	%
Maintenance and support services	62		47		15		32	%
Installation services	42		3		39		1300	%
Total service costs	118		50		68		136	%
Total cost of products sold and services	$	363	$	131	$	232	177	%

During the three months ended March 31, ~~2022, service costs were reasonably consistent with~~2023, hardware cost of products sold increased $164.0 thousand to $0.2 million compared to the same period in ~~the prior year.~~

~~Pharmacy Operations~~

~~Pharmacy operations consist of~~2022. The increase was primarily due to an $154.0 thousand increase in hardware costs incurred to operate retail pharmacies and our call center. Wages and salaries consist of compensation costs incurred for all pharmacy operations related employees and contractors including bonuses, health plans, severance, and contractor costs. Facility expenses consist of rent and utilities directly associated with ~~our pharmacy operations.~~

~~Other pharmacy operations expenses consist~~the increased number of ~~supply costs, and other costs.~~

Depreciation of property, plant and equipment includes depreciation on MedCenters, IT equipment, leasehold improvements, general plant and equipment, software, office furniture and equipment and vehicles. Amortization of intangible assets consists of amortization of mobile applications and software.

Three Months Ended March 31, 2022 vs. 2021
2022 2021 Amount Change % Change
Pharmacy operations expenses: (in thousands)
Wages and salaries $ 2,959 $ 2,135 $ 824 39 %
Rent, utilities, and other 502 171 331 194 %
Depreciation of property, plant and equipment 227 208 19 9 %
Amortization of intangible assets 122 34 88 259 %
Repairs and maintenance 119 45 74 164 %
Total pharmacy operations expenses $ 3,929 $ 2,593 $ 1,336 52 %
units sold during the three months ended March 31, 2023, as compared to the same prior year period.

During the three months ended March 31, ~~2022, pharmacy operations expenses~~2023, service costs increased ~~$1.3 million~~$68.0 thousand primarily due to ~~$3.9 million~~increased installation cost related to the sale of more MedCenters in the three months ended March 31, 2023, as compared, to the same period in 2021. This increase was primarily due to having one additional central pharmacy location in 2022 compared to the same period in 2021. Additionally, volume growth continued to ramp at existing pharmacy locations, thus increasing pharmacy personnel and supplies, resulting in increased wages, salaries, and operating costs. Amortization of intangible assets has increased asprior year period.

As a result of ~~deploying internally developed software in our~~the retail pharmacy ~~operations.~~services business exit, the Company met the requirements of ASC 205-20, to report the results of the retail pharmacy services business as a discontinued operation. Accordingly, the cost of products sold and services results for the retail pharmacy services business have therefore been reclassified as a discontinued operations within these condensed consolidated financial statements.

General and Administrative

General and administrative expenses consist of personnel costs, facility expenses and expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and share-based compensation. Facility expenses consist of rent and other related costs specific to our corporate and technology activities. Corporate insurance, office supplies and technology expenses are also captured within general and administrative expenses. We incurred and expect to incur ~~additional~~ expenses as a result of being a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.

We have a stock option plan whereby awards are granted to certain of our employees. The fair value of the stock options and restricted stock units granted by us to our employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. We measure the fair value of the stock options using the Black-Scholes option pricing model as of the grant date. Shares issued upon the exercise of

stock options and vesting of restricted stock units are new shares. We estimate forfeitures based on historical experience and expense related to awards is adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are expensed.


		Three Months Ended March 31,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
General and administrative expenses:	General and administrative expenses:	(in thousands)								General and administrative expenses:	(in thousands)
Wages and salaries	Wages and salaries	$	3,488	$	2,918	$	570	20	%	Wages and salaries	$	2,543	$	2,957	$	(414)	(14)	%
Professional services	Professional services	834		1,045		(211)		(20)	%	Professional services	919		591		328		55	%
Share-based compensation	Share-based compensation	569		260		309		119	%	Share-based compensation	618		569		49		9	%
Insurance	Insurance	508		458		50		11	%	Insurance	239		440		(201)		(46)	%
Software licenses and support	Software licenses and support	360		185		175		95	%	Software licenses and support	185		13		172		1323	%
Rent, utilities, and other	Rent, utilities, and other	569		539		30		6	%	Rent, utilities, and other	379		482		(103)		(21)	%

Office and IT supplies	Office and IT supplies	102		75		27		36	%	Office and IT supplies	39		40		(1)		(3)	%
Travel and other employee expenses	Travel and other employee expenses	72		155		(83)		(54)	%	Travel and other employee expenses	13		65		(52)		(80)	%
Depreciation of property, plant and equipment	Depreciation of property, plant and equipment	33		41		(8)		(20)	%	Depreciation of property, plant and equipment	25		33		(8)		(24)	%
Total general and administrative expenses	Total general and administrative expenses	$	6,535	$	5,676	$	859	15	%	Total general and administrative expenses	$	4,960	$	5,190	$	(230)	(4)	%

During the three months ended March 31, ~~2022,~~2023, general and administrative costs ~~increased~~decreased approximately ~~$0.9~~$0.2 million to ~~$6.5~~$5.0 million compared to the same period in ~~2021.~~2022. This ~~increase~~decrease was primarily due to ~~hiring additional administrative staff, increased share based compensation, as well as other investments necessary for~~reduction in wages and salaries of $0.4 million resulting from a reduced headcount and lower insurance costs of $0.2 million, partially offset by a $0.3 million increase in professional services costs related to our ~~growth as a public company.~~private placement funding and consultant support services within our finance department due to employee turnover.

Selling and Marketing

Selling and marketing expenses consist of personnel costs, marketing and advertising costs, and marketing related expenses for outside professional services. Wages and salaries consist of compensation costs incurred for all selling and marketing employees including our in clinic customer account managers, and contractors including bonuses, health plans, and severance.


		Three Months Ended March 31,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
Selling and marketing expenses:	Selling and marketing expenses:	(in thousands)								Selling and marketing expenses:	(in thousands)
Wages and salaries	Wages and salaries	$	2,094	$	1,362	$	732	54	%	Wages and salaries	$	112	$	59	$	53	90	%
Travel and other employee expenses	Travel and other employee expenses	130		38		92		242	%	Travel and other employee expenses	—		41		(41)		(100)	%
Marketing	Marketing	74		129		(55)		(43)	%	Marketing	20		—		20		100	%
Other selling and marketing expenses		15		5		10		200	%

Total selling and marketing expenses	Total selling and marketing expenses	$	2,313	$	1,534	$	779	51	%	Total selling and marketing expenses	$	132	$	100	$	32	32	%

During the three months ended March 31, ~~2022,~~2023, selling and marketing costs increased approximately ~~$0.8~~$0.03 million to ~~$2.3~~$0.1 million compared to the same period in ~~2021.~~2022. This increase was primarily due to ~~personnel related costs associated with hiring additional Clinic Account Managers (CAMs)~~a $0.1 million increase in salaries and ~~Regional Directors, which directly support the staff~~wages partially offset by a $0.04 million decrease in travel and ~~patients at the medical clinics where we are deployed.~~other employee expenses.

Research and Development

Research and development expenses represent costs incurred to develop and innovate our MedCenter platform technology, including development work on hardware, software and supporting information technology infrastructure. Wages and salaries consist of compensation costs incurred for research and development employees and contractors including bonuses, health plans, severance, and contractor costs.


		Three Months Ended March 31,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
Research and development expenses:	Research and development expenses:	(in thousands)								Research and development expenses:	(in thousands)
Wages and salaries	Wages and salaries	$	191	$	167	$	24	14	%	Wages and salaries	$	171	$	191	$	(20)	(10)	%
Other expenses	Other expenses	302		1		301		30,100	%	Other expenses	5		67		(62)		(93)	%
Total research and development expenses	Total research and development expenses	$	493	$	168	$	325	193	%	Total research and development expenses	$	176	$	258	$	(82)	(32)	%

2426

During the three months ended March 31, ~~2022,~~2023, research and development costs ~~increased~~decreased approximately ~~$0.3~~$0.1 million. This ~~increase~~decrease was primarily due to ~~ongoing~~the completion of prior period product improvement ~~activities, including efforts to integrate our MedPlatform® Enterprises Software with the EPIC pharmacy management system.~~activities.

Interest ~~Income and~~ Expense

Interest expense consists of accrued interest on outstanding debt and is payable monthly.


		Three Months Ended March 31,				2022 vs. 2021					Three Months Ended March 31,				2023 vs. 2022
		2022		2021		Amount Change		% Change			2023		2022		Amount Change		% Change
Interest income:		(in thousands)
Interest income		$	1	$	40	$	(39)	(98)	%
Total interest income		$	1	$	40	$	(39)	(98)	%
											(in thousands)
Interest expense:	Interest expense:									Interest expense:
Interest expense	Interest expense	$	(254)	$	(2)	$	(252)	12,600	%	Interest expense	$	169	$	251	$	(82)	(33)	%
Total interest expense	Total interest expense	$	(254)	$	(2)	$	(252)	12,600	%	Total interest expense	$	169	$	251	$	(82)	(33)	%

During the three months ended March 31, ~~2022,~~2023, interest expense ~~increased~~decreased $0.1 million compared to the same period in ~~2021~~2022, due to ~~entering into~~ a ~~term loan~~decrease in ~~June 2021. For more detail on~~ outstanding debt ~~and associated maturities, see Note 8~~during the 3 months ended March 31, 2023, as compared to the ~~unaudited consolidated condensed financial statements presented elsewhere~~same period in ~~this Quarterly Report on Form 10-Q.~~the prior year. Total outstanding debt principal was $2.0 million as of March 31, 2023, as compared to $10.0 million as of March 31, 2022.

Liquidity and Capital Resources

Sources of Liquidity

Since inception through March 31, ~~2022,~~2023, our operations have been financed primarily by net cash proceeds from the sale of stock and warrants from private placements, the sale of redeemable preferred stock and debt. As of March 31, ~~2022,~~2023, we had ~~$5.3~~$18.8 million in cash and cash equivalents and an accumulated deficit of ~~$205.1~~$257.0 million. ~~We added~~

On March 10, 2023, SVB, based in Santa Clara, California, was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. On March 10, 2023, the Federal Deposit Insurance Corporation (the “FDIC”) took control of SVB and created the National Bank of Santa Clara to ~~our liquidity resources~~hold the deposits of SVB after SVB was unable to continue their operations. SVB’s deposits are insured by the FDIC in ~~2021 through~~amount up to $250 thousand for any depositor and any deposit in excess of this insured amount could be lost. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that SVB depositors will have access to all deposited funds starting March 13, 2023.

On March 9, 2023, we closed a ~~senior secured term loan facility with Silicon Valley Bank~~private placement, or the ~~Loan Agreement,~~“Offering”, of securities with certain institutional investors pursuant to the terms of a definitive securities purchase agreement. The Offering consists of pre-funded warrants to purchase common stock (the “Pre-Funded Warrants”) issued upon closing at a price of $0.3212 per underlying share and are exercisable into shares of common stock at an exercise price of $0.01 per share, as well as, Series A warrants to purchase common stock an exercise price of $0.385440 per share (the “Series A Warrants”) to be issued following stockholder approval of the Offering. The issuance of the Series A Warrants (including the underlying shares of common stock) and the portion of the Pre-Funded Warrants in excess of 19.99% of the shares of Common Stock outstanding prior to the Offering are subject to approval by the stockholders of MedAvail.

The Pre-Funded Warrant shares are exercisable for an aggregate of up to 49,813,198 shares of common stock, and the Series A Warrants would be exercisable for an aggregate of up to 49,813,198 shares of common stock. Upon close of the transaction MedAvail received gross proceeds from the Offering of approximately $16 million, before deducting offering expenses. The Company intends to use the net proceeds from this offering to fund one-time costs associated with restructuring, repay outstanding debt, and finance MedAvail’s growth initiatives related to its MedCenter technology business.

On February 10, 2022 and March 29, 2023, the Company entered into the First Loan Amendment and Consent, and Letter Agreement, respectively, which provides waivers of any legal action or enforcement of rights and remedies with respect to the specified defaults enumerated therein, on and prior to February 10, 2023 and March 29, 2023. As of the date of this report, we ~~have borrowed $10.0 million~~are in ~~aggregate initial term loans.~~ compliance with all covenants under the terms of our Loan Agreement.

In April 2022, we completed a private placement, pursuant to which we received $40.0 million in gross proceeds before deducting placement agent commissions and other offering expenses. An additional $10.0 million in gross proceeds ~~is expected to close~~closed on July 1, ~~2022, subject to the satisfaction or waiver of certain conditions to closing.~~

2022. In connection with the private placement, we issued callable warrants in April 2022 and ~~expect to issue additional callable warrants in~~ July 2022. The warrant call option is exercisable by us beginning on each of the ~~12 month~~12-month and ~~24 month~~24-month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of our shares. If the warrants are exercised in full immediately after issuance by the Investors, we would receive additional gross

proceeds of up to $29.4 million. If we exercise our call option immediately after issuance, then we could raise upapproximately $19.6 million in gross proceeds.

In June, 2021 we added to our liquidity resources through a senior secured term loan facility with SVB, or the Loan Agreement, pursuant to which we borrowed $10.0 million in aggregate initial term loans. In December 2022, and February 2023, the Company made discretionary principal payments to reduce our senior secured term loan by $5.0 million and $3.0 million, respectively. In conjunction with the $3.0 million principal payment an additional ~~$19.6 million.~~$0.4 million was paid related to required final payments. For more detail on outstanding debt and associated maturities, see Part I, Item I,. Note 8 in this report of our unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q and Note 13 and Note 21 in our Annual Financial Statements presented in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC, on April 14, 2023.

As of March 31, 2023, we had approximately $9.8 million on deposit with SVB and $9.7 million on deposit with another financial institution. We do not anticipate a material impact on our financial condition, operations or Loan and Security Agreement with SVB. We continue to monitor the circumstances surrounding SVB. As of the date of this filing we have full access to and control over all our cash and, cash equivalents across all financial institutions.

Management is ~~also~~continuously exploring additional sources of financing, the success of which is dependent on market conditions. ~~Management has concluded that the aforementioned conditions, including the ongoing uncertainty related~~In continued efforts to ~~the~~address negative impacts offrom the ~~COVID-19 pandemic~~economy, and the economic uncertainties related to the conflict in Ukraine resulting from the military actions of Russia, including on the global economy, interest rate fluctuations, inflationary pressures and our supply chain, ~~raise~~management is looking to others financial strategies such a stock splits and warrant exercise, should market conditions allow. Given our recent private placement and reduction in operating cost due to the disposition of our retail pharmacy services business, management believes there is no substantial doubt about our ability to continue as a going concern within 12 months from the date of issuance of the financial statements. ~~Our plans to address this uncertainty include raising additional funding, as necessary, through public or private equity or debt financings.~~

~~However, we may not be able to secure additional financing in a timely manner or on favorable terms, if at all.~~

Furthermore, if we issue equity securities to raise additional funds, our existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of our existing stockholders. Failure to raise capital, however, as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Our management actively evaluates matters of liquidity and growth capital needs, including evaluating debt and equity as sources of growth capital with a focus on lower overall weighted average cost of capital and favorable financing terms. Our primary uses of liquidity are operating activities, capital expenditures, and lease payments.

Cash Flows

The following table summarizes our cash flows for the three months ended March 31, ~~2022~~2023 and ~~2021:~~2022:


		Three Months Ended March 31,				2022 vs. 2020					Three Months Ended March 31,				2022 vs. 2020
(In thousands)	(In thousands)	2022		2021		Amount Change		% Change		(In thousands)	2023		2022		Amount Change		% Change
Cash used in operating activities	Cash used in operating activities	$	(13,264)	$	(9,830)	$	(3,434)	35	%	Cash used in operating activities	$	(5,210)	$	(13,264)	$	8,054	(61)	%
Cash used in investing activities	Cash used in investing activities	(852)		(712)		(140)		20	%	Cash used in investing activities	(17)		(852)		835		(98)	%
Cash (used in) provided by financing activities		(23)		189		(212)		(112)	%
Net decrease in cash and cash equivalents, and restricted cash		$	(14,139)	$	(10,353)	$	(3,786)	37	%
Cash provided by (used in) financing activities										Cash provided by (used in) financing activities	12,579		(23)		12,602		(54791)	%
Net increase (decrease) in cash and cash equivalents, and restricted cash										Net increase (decrease) in cash and cash equivalents, and restricted cash	$	7,352	$	(14,139)	$	21,491	(152)	%

Operating Activities

During the three months ended March 31, ~~2022,~~2023, cash used in operating activities ~~increased $3.4~~decreased $8.1 million to ~~$13.3~~$5.2 million compared to the same period in ~~2021.~~2022. The ~~increase~~decrease in cash used in operating activities was primarily due to ~~an increase~~exiting the retail pharmacy business in ~~inventory,~~January 2023, with reduced operating ~~expenses from wages and salaries, and costs attributable~~activities during the three months ended March 31, 2023, as compared to the ~~launch and growth of our retail pharmacy operations~~same period in ~~Arizona, California, Michigan, and Florida, and operating as a public company.~~the prior year.

Investing Activities

During the three months ended March 31, ~~2022,~~2023, cash used in investing activities ~~increased $0.1~~decreased $0.8 million to ~~$0.9~~$0.02 million compared to the same period in ~~2021.~~2022. The ~~increase~~decrease during the three months ended March 31, 2023 was primarily due to an ~~increase~~decrease in investment in property, plant and equipment and intangible software assets ~~associated with investments in Retail Pharmacy Services operations in Arizona, California, Michigan, and Florida.~~as compared to the same prior year period.

Financing Activities

During the three months ended March 31, ~~2022,~~2023, cash provided by financing activities ~~decreased $0.2~~increased $12.6 million to ~~$0.0 million~~ compared to the same period in ~~2021. During the three months ended March 31, 2021, the activity was~~2022. The increase is primarily ~~from the issuance of common stock~~ due to the ~~exercise~~$16.0 million of ~~options and warrants,~~funds received pursuant the Offering of securities with ~~no similar activity~~certain institutional investors. This increase of funds was partially offset by a $3.0 million payment on our senior secured term loan with SVB during the three months ended March 31, ~~2022.~~2023.

~~Critical Accounting Estimates~~Cash Flows Related to Discontinued Operations

~~There were no significant changes in our critical accounting estimates in~~

As a result of the retail pharmacy services business exit, the Company met the requirements of ASC 205-20 to report the results of the retail pharmacy services business as a discontinued operation. Accordingly, the cash flows from discontinued operations are as noted below and within these condensed consolidated financial statements.

Cash provided by operating activities by the pharmacy services business totaled $3.5 million and $0.1 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Cash used in investing activities from ~~those previously disclosed~~the pharmacy services business totaled $0.02 million and $0.35 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Cash used in financing activities from the pharmacy services business totaled $0.03 million and $0.02 million for the three months ended March 31, 2023 and March 31, 2022, respectively. Depreciation and amortization expense of the pharmacy services business totaled $0.75 million and $0.48 million for the three months ended March 31, 2023 and March 31, 2022, respectively.

Critical Accounting Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. We believe that the estimates, assumptions and judgments involved in the accounting policies described below have the greatest potential impact on our consolidated financial statements and, therefore, we consider these to be our critical accounting estimates. Accordingly, we evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions. Please refer to Note 4 in our consolidated financial statements included in Item 8 of our Annual Report on Form 10-K for information about our significant accounting policies, and Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, filed with the SEC on April 14, 2023.

Critical estimates in applying the Company’s accounting policies

Derivative Warrant Liabilities

The Pre-Funded Warrants and Series A Warrants do not meet the equity classification requirements under ASC 815 - Derivative and Hedging, specifically the Company did not have a sufficient amount of Common Stock available to be issued to settle the warrants upon grant and through March ~~29, 2022.~~31, 2023, due to the Nasdaq 19.99% cap that limits the Company's ability to issue Common Stock to settle the Series A Warrants and Pre-funded Warrants. Consequently, the Pre-Funded Warrants and Series A Warrants were classified as liabilities and therefore measured at fair value. The Company uses the Black-Scholes pricing model to estimate fair value of these warrants at issuance and at each exercise and period end date. The key assumptions used in the model are the expected future volatility in the price of the Company’s shares, exercise price of the warrants, risk free rates relative to the expected life of the warrants, and the expected life of the warrants. The impact of changes in key assumptions as described see Part I, Item I, Note 12 in this report of our unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, see Part II, Item 8, Note 5 of our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, filed with the SEC on ~~March 29, 2022,~~April 14, 2023, and Note 4: "Recent Accounting Pronouncements" in the notes to our unaudited condensed consolidated ~~condensed~~ financial statements included elsewhere in this Quarterly Report Form 10-Q.

2629

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, ~~(as~~as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of March 31, 2023, the end of the period covered by this ~~report.~~ Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of ~~the end of such period,~~March 31, 2023, our disclosure controls and procedures were not effective because of the material weakness in our internal control over financial reporting described below.

In connection with the preparation of our Annual Report on Form 10-K for the year ended December 31, 2022, our management identified the following material weakness in our internal control over financial reporting that caused management to conclude that, as of December 31, 2022, our disclosure controls and procedures were not effective:

•Our initial supporting documentation for certain technical accounting matters did not adequately address the appropriate accounting guidance, which was indicative of a lack of controls relating to our financial reporting process, including the evaluation and analysis of accounting treatment for complex, non-standard transactions.

The material weakness identified in connection with the preparation of our Annual Report on Form 10-K had not been fully remediated as of March 31, 2023.Notwithstanding the material weakness in our internal control over financial reporting as of March 31, 2023, management has concluded that the condensed consolidated financial statements included in this report present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.

Remediation of Material Weakness

We recognize the importance of the control environment. Consequently, we are ~~effective.~~designing and implementing remediation measures to address the material weakness and enhance our internal control over financial reporting. Management is taking the following actions, which we believe will remediate the material weakness:

•We are designing and implementing additional controls relating to (i) the preparation of initial supporting documentation for certain technical accounting matters in order to adequately address the appropriate accounting guidance, including the evaluation and analysis of accounting treatment for complex, non-standard transactions, and (ii) the engagement of external consultants to provide support and assistance in our evaluation of complex, non-standard transactions.

Changes in Internal Control Over Financial Reporting

There ~~have not~~has been ~~any changes~~no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, ~~2022~~2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.The material weakness associated with our financial reporting discussed above did not result in the initiation of remediation activities until after March 31, 2023.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

2730

PART II

Item 1. Legal Proceedings

The information set forth under the heading “Legal” in Note 10, Commitments and Contingencies, in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.

Item 1A. Risk Factors

~~There~~Except as set forth below, there have been no material changes ~~from~~to the risk factors disclosed in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, or the ~~“2021~~2022 Annual Report, filed with the Securities and Exchange Commission on ~~March 29, 2022.~~April 14, 2023. The risk factors described in our ~~2021~~2022 Annual Report, as well as other information set forth in this Quarterly Report on Form 10-Q, could materially adversely affect our business, financial condition, results of operations and prospects, and should be carefully considered. The risks and uncertainties that we face, however, are not limited to those described in the ~~2021~~2022 Annual Report. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business and the trading price of our securities.

Our share price does not meet the minimum bid price for continued listing on Nasdaq. Our ability to continue operations or to publicly or privately sell equity securities ~~particularly in light~~and the liquidity of our common stock could be adversely affected if we do not regain compliance with the minimum bid price requirement and we are delisted from Nasdaq.

On October 31, 2022, we received a deficiency letter from Nasdaq notifying us that for the prior 30 consecutive business days the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had 180 calendar days starting on October 31, 2022, or until May 1, 2023, to regain compliance with the Bid Price Rule. On May 2, 2023, Nasdaq informed us of its decision to extend the period for us to regain compliance with the Bid Price Rule by an additional 180 calendar days, or until October 30, 2023. If, at any time before October 30, 2023, the bid price for our common stock closes at $1.00 or more for a minimum of 10 consecutive business days, we will regain compliance with the Bid Price Rule, unless the Nasdaq staff exercises its discretion to extend this 10-day period pursuant to Nasdaq listing rules. We have not regained compliance with Nasdaq Listing Rules as of the ~~fast-changing nature~~filing date of this Quarterly Report on Form 10-Q.

We intend to regain compliance with the Bid Price Rule by implementing a reverse stock split of our common stock at a ratio in the range of not less than 1-for-30 and no greater than 1-for-80, with such ratio to be determined in the discretion of our board of directors or a duly authorized committee thereof. Our stockholders will vote on a proposal to approve the reverse stock split at our annual meeting of stockholders scheduled for June 14, 2023. There is no guarantee that the reverse stock split will be approved by our stockholders or that a reverse stock split will allow us to regain compliance with the Bid Price Rule, and a reverse stock split could result in an adverse effect on or negatively impact the price of our common stock.

If we do not regain compliance with the Bid Price Rule and are not eligible for or are not granted an additional compliance period, our common stock may be delisted. There can be no assurance that, if we receive a delisting notice and appeal the delisting determination by the Nasdaq staff, such appeal would be successful. There can be no assurance that we will maintain compliance with the other requirements for listing our common stock on Nasdaq.

Delisting could adversely affect our ability to raise additional capital through the public or private sale of equity securities, and could significantly affect the ability of investors to trade our securities, which would negatively affect the value and liquidity of our common stock.

We and our stockholders could be materially adversely impacted if our common stock is delisted from Nasdaq. In particular:

•we may lose the confidence of our current or prospective third-party providers and collaboration partners, which could jeopardize our ability to enter into supply, manufacturing, licensing, and collaboration agreements and continue our business as currently conducted;

•we could be in a material breach under agreements we have with third parties, such as the Loan and Security Agreement between us and Silicon Valley Bank;

•the price of our common stock will likely decrease;

•stockholders may be unable to sell or purchase our common stock when they wish to do so;

•the potential loss of confidence by employees;

•we may lose the interest of institutional investors in our common stock;

•we may have fewer business development opportunities;

•we may lose the interest of institutional investors in our common stock;

•we may have fewer business development opportunities;

•we may lose media and analyst coverage;

•our common stock could be considered a “penny stock,’ which would likely limit the level of trading activity in the secondary market for our common stock; and

•we would likely lose the active trading market for our common stock, as it may only be traded on one of the ~~COVID-19 pandemic, containment measures and the related impacts to economic and operating conditions.~~over-the counter markets, if at all.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

2832

Item 6. Exhibits

Incorporated by Reference
Exhibit Number Description Form Exhibit Filing Date
4.1
Form of Common Stock Purchase Warrant issued by MedAvail, Inc.
8-K 4.1 November 18, 2020
4.2
Amended and Restated Investors’ Rights Agreement by and among the Registrant, MedAvail, Inc., and certain stockholders, dated October 9, 2020
S-4/A 4.9 October 9, 2020
4.3
Form of Common Stock Purchase Warrant issued by the Registrant to H.C. Wainwright & Co., LLC or its affiliates
8-K 4.3 November 18, 2020
4.4
Securities Purchase Agreement, dated as of March 30, 2022
8-K 10.1 April 4, 2022
4.5
Registration Rights Agreement, dated as of March 30, 2022
8-K 10.2 April 4, 2022
4.6
Form of Warrant
8-K 10.3 April 4, 2022
10.1#§
Offer Letter by and between the Registrant and Mark Doerr
8-K 10.1 January 11, 2022
10.2#§
Change of Control and Severance Agreement by and between the Registrant and Mark Doerr
8-K 10.2 January 11, 2022
10.3#§
Transition Services Agreement between the Company and Ed Kilroy
8-K 10.3 January 11, 2022
10.4#§
Offer Letter between the Company and Steven Hess
8-K 10.1 February 22, 2022
10.5#§
Change of Control and Severance Agreement between the Company and Steven Hess
8-K 10.2 February 22, 2022
10.6#
MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements.
8-K 10.1 April 8, 2022
31.1*
Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*
Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**
Certifications of Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101* Inline XBRL Document Set for the consolidated condensed financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q
104* Inline XBRL for the cover page of this Quarterly on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set

Incorporated by Reference

Exhibit Number

Description

Form

Exhibit

Filing Date

3.1

Amended and Restated Certificate of Incorporation of MedAvail Holdings, Inc.

8-K

3.1

June 16, 2022

3.2

Amended and Restated Bylaws of MedAvail Holdings, Inc.

8-K

3.2

November 18, 2020

4.1

Securities Purchase Agreement, dated as of March 9, 2023

8-K

10.1

March 14, 2023

4.2

Registration Rights Agreement, dated as of March 9, 2023

8-K

10.2

March 14, 2023

4.3

Form of Pre-Funded Warrant to Purchase Common Stock

8-K

10.3

March 14, 2023

4.4

Form of Series A Warrant to Purchase Common Stock

8-K

10.4

March 14, 2023

4.5

Warrant to Purchase Stock dated February 10, 2023 issued to Silicon Valley Bank

8-K

10.2

February 16, 2023

4.6

Warrant to Purchase Stock dated February 10, 2023 issued to SVB Innovation Credit Fund VIII, L.P.

8-K

10.3

February 16, 2023

10.1#

Separation Agreement and Release by and between MedAvail Holdings, Inc. and Steven Hess

8-K

10.1

February 10, 2023

10.2#

Separation Agreement and Release by and between MedAvail Holdings, Inc. and Matt Broome

8-K

10.2

February 10, 2023

10.3

First Amendment, Consent and Default Waiver to Loan and Security Agreement dated February 10, 2023, by and among MedAvail Holdings, Inc., MedAvail Pharmacy, Inc., MedAvail, Inc., MedAvail Technologies (US) Inc., MedAvail Technologies, Inc., Silicon Valley Bank, and SVB Innovation Credit Fund VIII, L.P.

8-K

10.1

February 16, 2023

10.4

Letter Agreement dated March 29, 2023

8-K

10.1

April 3, 2023

31.1*

Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**

Certifications of Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101*

Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q

104*

Inline XBRL for the cover page of this Quarterly on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set

~~§ Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) and Item 601(b)(10).~~

# Indicates a management contract or compensatory plan.

* Filed herewith.

** Furnished herewith.

2933

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

behalf by the undersigned thereunto duly authorized.


	MEDAVAIL HOLDINGS, INC.

Date: May ~~13, 2022~~18, 2023	By:	/s/ Mark Doerr
		Mark Doerr
		President and Chief Executive Officer ~~and~~ (Principal Executive ~~Officer~~Officer)

	By:	/s/ Ramona Seabaugh
		Ramona Seabaugh
		Chief Financial Officer ~~and~~ (Principal Financial ~~Officer~~and Accounting Officer)

3034


	Three Months Ended March 31, 2021
	Current presentation		As previously reported		Change
Pharmacy operations	$	2,593	$	1,911	$	682
General and administrative	5,676		6,515		(839)
Selling and marketing	1,534		1,377		157
	$	9,803	$	9,803	$	—


			Fair Value Hierarchy
(in thousands)	March 31, 2022		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	5,274	$	5,274	$	—	$	—
Restricted cash	676		676		—		—
Total assets	$	5,950	$	5,950	$	—	$	—


			Fair Value Hierarchy
(in thousands)	December 31, 2021		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	19,689	$	19,689	$	—	$	—
Restricted cash	400		400		—		—
Total assets	$	20,089	$	20,089	$	—	$	—


	Retail Pharmacy Services		Pharmacy Technology		Total
Three Months Ended March 31, 2022
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue	$	8,849	$	—	$	8,849
Hardware	—		56		56
Subscription	—		109		109
Total pharmacy and hardware revenue	8,849		165		9,014
Service revenue:
Software integration	—		—		—
Software	—		48		48
Maintenance and support	—		32		32
Installation	—		6		6
Professional services and other	—		14		14
Total service revenue	—		100		100
Total revenue	8,849		265		9,114
Cost of products sold and services	8,482		131		8,613
Segment gross profit	$	367	$	134	501
Operating Expense:
Pharmacy operations					3,929
General and administrative					6,535
Selling and marketing					2,313
Research and development					493
Total operating expense					13,270
Operating loss					$	(12,769)


	Retail Pharmacy Services		Pharmacy Technology		Corporate		Total
March 31, 2022
Assets	$	16,323	$	6,661	$	4,708	$	27,692
Liabilities	$	6,705	$	4,183	$	10,189	$	21,077
December 31, 2021
Assets	$	13,641	$	5,222	$	19,280	$	38,143
Liabilities	$	5,618	$	3,567	$	9,885	$	19,070